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ABSTRACT
Heart- and  Liver-Type Fatty Acid Binding Proteins in Lipid and Glucose Metabolism.
(August 2004)
Erdal Erol, D.V.M., Firat University;
M.S., University of Missouri
Chair of Advisory Committee: Dr. Bert Binas
Heart-type Fatty Acid-Binding Protein (H-FABP) is required for high rates of
skeletal muscle long chain fatty acid (LCFA) oxidation and esterification. Here we
assessed whether H-FABP affects soleus muscle glucose uptake when measured in vitro
in the absence of LCFA. Wild type and H-FABP null mice were fed a standard chow or
high fat diet before muscle isolation. With the chow, the mutation increased insulin-
dependent deoxyglucose uptake by 141% (P<0.01) at 0.02 mU/ml of insulin, but did not
cause a significant effect at 2 mU/ml insulin; skeletal muscle triglyceride and long chain
acyl-CoA (LCACoA) levels remained normal. With the fat diet, the mutation increased
insulin-dependent deoxyglucose uptake by 190% (P<0.01) at 2 mU/ml insulin, thus
partially preventing insulin resistance, and completely prevented the threefold (P<0.001)
diet-induced increase of muscle triglyceride levels; however, muscle LCACoA levels
showed little or no reduction. With both diets, the mutation reduced the basal (insulin-
independent) soleus muscle deoxyglucose uptake by 28% (P<0.05). These results
establish a close relationship of FABP-dependent lipid pools with insulin sensitivity, and
indicate the existence of a non-acute, antagonistic, and H-FABP-dependent fatty acid
regulation of basal and insulin-dependent muscle glucose uptake. 
iv
Liver fatty acid binding protein (L-FABP) has been proposed to limit the
availability of chain LCFA for oxidation and for peroxisome proliferator-activated
receptor (PPAR-alpha), a fatty acid binding transcription factor that determines the
capacity of hepatic fatty acid oxidation. Here, we used L-FABP null mice to test this
hypothesis. Under fasting conditions, this mutation reduced β-hydroxybutyrate (BHB)
plasma levels as well as BHB release and palmitic acid oxidation by isolated hepatocytes.
However, the capacity for ketogenesis was not reduced: BHB plasma levels were
restored by octanoate injection; BHB production and palmitic acid oxidation were normal
in liver homogenates; and hepatic expression of key PPAR-alpha target (MCAD,
mitochondrial HMG CoA synthase, ACO, CYP4A3) and other (CPT1, LCAD) genes of
mitochondrial and extramitochondrial LCFA oxidation and ketogenesis remained at wild-
type levels. These results suggest that under fasting conditions, hepatic L-FABP
contributes to hepatic LCFA oxidation and ketogenesis by a nontranscriptional
mechanism. 
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1CHAPTER I
INTRODUCTION
LCFAs and their metabolism
Lipids are a chemically diverse group of compounds. Their common feature is
insolubility in water. They are classified into different categories and have diverse
biological functions; fatty acids (FAs), which are carboxylic acids, are the principle
stored form of energy in many organisms whereas phospholipids and sterols are
partitioned into biological membranes.  Other lipids are found in relatively small
amounts in cells and  play crucial roles as enzyme cofactors (vitamin K), detergents (bile
acids) pigments (retinal), hydrophobic anchors (covalently attached fatty acids and
phosphatidylinositol), hormones (vitamin D derivatives) and intracellular messengers
(eicosanoids). 
 FAs are highly reduced compounds with hydrocarbon chains of 4 to 36 carbons
with an energy of complete oxidation (~38kJ/g) more than twice that for the same
weight of carbohydrate or protein. In some FAs, this chain is fully saturated (contains no
double bonds) and unbranched; others contain one or more double bonds. Because of
their hydrophobicity and extreme insolubility in water, they segregate into lipid droplets
in the form of triacylglycerols (TG), which do not raise the osmolarity of the cytosol.
TGs contain three FA molecules esterified to the three-hydroxyl groups of glycerol. The
relative chemical inertness of TGs allow their intracellular storage in large quantities, 
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2but not extreme quantities, without the risk of undesired chemical reactions with other
cellular components.
Cells that derive energy from the oxidation of FAs may obtain FAs from three
sources, namely, fats in diet, fat stores in cells and fats in newly synthesized in cells (de
novo synthesis).  Because of their insolubility in water, TGs taken by food must be
emulsified before they can be digested by water-soluble enzymes in intestines. Bile salts
synthesized from cholesterol in liver help convert dietary fats into mixed miscelles of bile
salts and TGs. Lipid molecules are more accesible to the action of water-soluble lipases
in intestines. Here, TGs are converted into monoglycerides, DGs, free FAs and glycerol.
These compounds are small enough to diffuse into the epithelial cells lining the intestinal
mucosa, where they are reconverted into TGs and packaged with dietary cholesterol and
lipid-binding proteins, called apoliproteins, agregating into chylomicrons. These
chylomicrons go through from the lymphatic system, from which they enter the blood
and are carried to muscle, adipose tissues and liver. The extracellular enzyme lipoprotein
lipase is activated by apoprotein C-II, enabling hydrolysis of TGs into mainly long chain
FAs (LCFAs) and glycerol. FAs are ultimately oxidized for energy or reesterified for
storage as TGs, depending on the physiological condition of the individual. When the
diets contain more FAs than are needed immediately for fuel or precursors, they are
converted into TGs in the liver, and TGs are packaged with specific apoliproteins into
very-low density lipoproteins (VLDLs).  VLDLs are transported in blood from the liver
to adipose tissues, where the TGs are removed and stored in lipid droplets within
adipocytes. 
3 Although most cells are capable of de novo FA synthesis, cells with large
requirements for FA beta-oxidation, such as cardiac and skeletal myocytes, rely on
import of exogenous LCFAs to provide this critical metabolic fuel. Cells that store
potential energy in the form of TGs, such as adipocytes, have efficient mechanisms for
both LCFA import and export. Since most tissues contain only small amounts of storage
lipids, energy production depends on a continuous supply of FAs, mostly from adipose
tissues. The capacity of mammalians to store these LCFAs as triglycerides (TGs) in
cytosolic lipid droplets is an important adaptation for survival during periods of
nutritional deprivation.  In adipose tissue, FAs are produced by lipolysis, transported
bound to albumin in blood and taken up by tissues through passive diffusion or in a
process mediated by transport proteins in the plasma membrane, as explained above.
Once within the cells, free FAs are reportedly bound to fatty acid binding proteins
(FABPs) which are abundant in the cytosol (Ockner and Manning, 1982), depending on
the tissue and its metabolic demand. FAs are either converted to TGs, diglycerides
(DGs), membrane phospholipids or oxidized in mitochondria for energy production.
For a long time it was believed that the transport of FAs into the muscle cell was
purely a passive process. This was based on early observations that FA uptake increased
linearly with FA concentration. Recently, specific carrier proteins have been identified in
various tissues, including skeletal muscle.  In the sarcolemma, two proteins have thus far
been identified that are involved in the transport of FAs across the membrane but their
functional significances are still unclear. These proteins are a specific plasma membrane
FA binding protein (FABPpm) (Sorrentino et al., 1988) and a FA translocase protein
(FAT/CD36) (Abumrad et al., 1993). A third protein has been identified (FA transport
4protein, FATP) (Schaffer and Lodish, 1994), but its transport role is still under
investigation. It is worth noting, however, that not only LCFAs but also far more
hydophobic compounds, such as phospholipids and cholesterol, are fully capable of inter-
membrane transfer in the absence of any binding protein whatsoever (Brown, 1992).
Cytosolic transport of LCFAs to various intracellular organelles including
mitochondria may be mediated by FABPs (Figure I.1). In considering a transport function
for the FABPs in the cytoplasm, the intracellular FABPs have been proposed as
transporters of LCFAs in the soluble cytoplasm (Storch and Thumser, 2000).  The notion
that these proteins function as intracellular transporters originally derived from the
assumption that hydrophobic LCFAs would require a transport protein for transit in an
aqueous milieu such as cytoplasm. LCFAs are released from the LCFAs-FABP complex
when they reach their final destinanation in the cytoplasma and either esterified in the
cytoplasma or oxidized in mitochondria. 
 LCFAs in the cytoplasma may be activated by the enzyme acyl-CoA synthethase
to form an acyl-CoA complex. For oxidation, this acyl-CoA complex can be bound to
carnitine under the influence of the enzyme carnitine palmitoyl transferase I (CPT I),
which is located at the outside of the outer mitochondrial membrane (Schulz, 1985). The
binding of carnitine with the activated LCFA is the first step in the transport of the LCFA
into the mitochondria. As carnitine binds to the acyl-CoA moiety, free CoA is released.
The acyl-carnitine complex is transported with a translocase and reconverted into acyl-
CoA at the matrix side of the inner mitochondrial membrane by the enzyme carnitine
palmitoyl transferase II (CPT II). The carnitine that is released diffuses back across the
5into acyl- CoA at the matrix side of the inner mitochondrial membrane by the enzyme
carnitine palmitoyl transferase II (CPT II). The carnitine that is released diffuses back
across the mitochondrial membrane into the cytoplasm and thus becomes available again
for the transport of other LCFAs. 
The oxidation of LCFAs to Acetyl-CoA in mitochondria is a central energy-
yielding pathway in mammals. The electrons removed during FA oxidation pass through
the mitochondrial respiratory chain, beta-oxidation, driving ATP synthesis. The acetyl
CoA produced from the FAs may be completely oxidized to carbon dioxide via the citric
acid cycle, resulting in further energy production. Acetyl CoA can also be converted in
liver into ketone bodies-water soluble fuels exported to the extrahepatic tissues such as
brain and muscles when glucose is not available. 
Regulation of LCFA metabolism
It has been proposed that the regulation of FAs take place at several levels such as the
cell membrane, the mitochondrial membrane and through transcriptional regulation. FA
transporters are likely to be responsible for some of the transport of FA across the
sarcolemma, and these transporters can be regulated both acutely and chronically.
Recently, Bonen et al. (2000) demonstrated that FAT/CD36 can translocate from
intracellular vesicles to the cell membrane in a similar manner as the GLUT-4 protein,
indicating that FA transport can be regulated. Along with a higher density of FAT/CD36
at the cell membrane, an increased LCFA transport into the cell has been observed. At
present, however, it is not known if there are any physiological situations in which this
transport becomes limiting. It is also not known what the triggers are inside the cell for
the up- or down-regulation of transport proteins such as cytosolic FABPs.
6     Figure I.1: Fatty acid metabolism and FABPs (from Glatz et al., 2003).
7It is generally believed that CPT I is the rate-limiting enzyme in the transport of
LCFAs across the mitochondria and may be even rate-limiting for FA oxidation
(Ruderman and Dean, 1998). There is substantial evidence that CPT I activity is
influenced by numerous regulators. The most important regulator of CPT I activity is
malonyl-CoA concentration.
  A large number of in vitro studies have now established a role for malonyl-CoA
in regulating the entry of LCFAs into the mitochondria in a variety of tissues, including
skeletal muscle (Rewieved by Saha and Ruderman, 2003). Malonyl-CoA is a potent
inhibitor of CPT I and is thus a potential candidate for the regulation of fat metabolism
(McGarry and Brown, 1997). Malonyl-CoA is formed from acetyl-CoA, a reaction
catalyzed by the enzyme acetyl-CoA carboxylase (ACC). Malonyl-CoA levels decrease
in rodent skeletal muscle from rest to moderate intensity exercise, when energy
production from fat increases. It is believed that the resting concentrations of malonyl-
CoA are sufficiently high to inhibit CPT I, and a decrease in the malonyl-CoA
concentration would therefore result in a relief of the inhibition of CPT I and increased
LCFA transport into the mitochondria. It is also well known that acetyl-CoA
concentration in the muscle increases rapidly at the onset of high-intensity exercise,
which will stimulate the activity of ACC as it is the primary substrate for this enzyme.
The resulting increased concentration of malonyl-CoA could possibly explain a reduced
FA uptake into the mitochondria.  It should also be mentioned that activation of
adenosine monophosphate (AMP)-activated protein kinase (AMPK)-activated protein
kinase increases fatty acid oxidation by lowering the concentration of Malonyl-CoA
(Ruderman et al., 2003).
8There are  now many evidences that peroxisome proliferator-activated receptors
(PPARs), members of the ligand-activated nuclear receptor superfamily, exert their
major influences on lipid and glucose metabolism (reviewed by Ferre, 2004). PPARs
selectively modulate cellular and tissue capacities for FA acid oxidation by acting as
lipid sensors. They bind to specific recognition sites known as peroxisome proliferator-
activated receptor response elements- PPREs, located in regulatory regions of certain
target genes. Most PPREs have been identified in the promoters of genes encoding
proteins related to FA oxidation and transport of FA synthesis. At least three different
PPARs have now been identified, i.e. PPAR- alpha, PPAR-gamma, and PPAR-delta),
which exert their regulatory function directly at the level of gene expression (Kliewer et
al., 1997). It has been suggested that PPAR- alpha activation stimulates FA catabolism
by inducing L-FABP expression (Kaikaus et al., 1993; Isseman et al., 1992). PPAR-delta
has been suggested to mediate the effects of LCFAs  in pre-adipocytes, thereby inducing
adipogenesis. However the effects of FAs may be mediated exclusively through PPAR-
gamma (Hu et al., 1995), or perhaps a combination of PPAR-delta and PPAR-gamma
(Ailhaud, 1997).
Regarding regulation of FA synthesis, the reaction catalyzed by acetyl CoA
carboxylase (ACC) is the rate-limiting step in the synthesis of fatty acids and this
enzyme has important regulatory function. When there is an increase in the
concentration of mitochondrial acetyl-CoA and of ATP, citrate is transported out of the
mitochondria and becomes both the precursor of cytosolic Acetyl-CoA and an allosteric
signal for the activation of ACC.
9ACC is also regulated by covalent alteration. Hormones like glucagon and
epinephrine trigger phosphorylation, which slows down FA synthesis. Other enzymes in
the FA synthesis pathway are also regulated. The pyruvate dehydrogenase complex and
citrate lyase, both of which supply acetyl-CoA, are activated by insulin through a
cascade of protein phosphorylation.  The rate of TG biosynthesis is profoundly altered
by the action of several hormones. Insulin promotes the conversion of carbohydrates
into TGs. People with severe diabetes, due to the failure of insulin secretion or action,
not only are unable to use glucose properly but also fail to synthesize fatty acids from
carbohydrates or amino acids. TG metabolism is also influenced by glucagon, growth
hormone and adrenal corticol hormones. 
Recent data strongly suggest that sterol regulatory element binding protein-1c
(SREBP-1c) is a key transcription factor that activates transcription of genes involved
with fatty acid synthesis (reviewed by Horton, 2002). SREBPs directly activate the
expression of more than 30 genes related to the synthesis and uptake of FAs, cholesterol,
TGs and phospholipids (PLs). It has been suggested that SREBP-1c mediates insulin’s
lipogenic action in liver. Insulin decreases the transcription of genes encoding
gluconeogenic enzymes and increases lipogenic enzymes such as fatty acid synthase and
ACC. Recent studies suggest that many of these transcriptional changes may be
mediated by an increase in the levels of transcripton factor SREBP-1c, whose mRNA
levels are increased by insulin (Kim et al., 1998; Foretz et al., 1999; Shimomura et al.,
1999).  The liver is the responsible organ for convertion of excess carbohydrates to FAs
to be stored or burned in muscle. In carbohydrate excess, insulin stimulates the FA
synthesis in liver and insulin’s stimulatory effect on lipid synthesis is mediated by an
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increase in SREBP-1c. Dominant negative forms of SREBP1 can block expression of
these gluconeogenic and lipogenic enzymes (Foretz et al., 1999), whereas
overexpression  can increase their expression (Shimomura et al., 1999).
FABPs
FABPs in mammalian cells  were discovered more than 30 years ago as a small
(13-15 kDa), non-enzymatic cytoplasmic proteins which bind long-chain fatty acids in
vitro (Ockner et al., 1972; Mishkin et al., 1972). So far, they have been now classified in
at least eight distinct types (Table I.1). FABPs from intestine (I-FABP) (Ockner et al.,
1972), liver (L-FABP) (Mishkin et al., 1972) and heart (H-FABP) (Fournier et al., 1978)
were the first of the family being characterized. Despite the relevant structural
similarities among all of them, each member presents distinct features, particularly in the
way they bind the ligand in these tissues. FA flux is substantial in all above-mentioned
organs and thus it was proposed that FABPs are necessary for intracellular binding and
transport of LCFAs. There are some other proposed functions for FABPs such as, (a)
modulation of specific enzymes of lipid (Storch and Thumser, 2000) and maintenance of
low FA concentrations in metabolic pathways, either anabolic or catabolic (Kaikaus et
al., 1990); (b) maintenance of cellular membrane FA levels (Glatz et al., 1995); and (c)
regulation of the expression of FA-responsive genes (Glatz and Van der Vusse, 1996).
Within these categories, numereous more specific functional roles may be assigned to
these proteins. For instance, FABPs may modulate lipid metabolism via an involvement
in the FA uptake or export process, by regulation of substrate and/or product
11
Table I.1: The mammalian fatty acid binding protein family (modified from Storch and
Thumser, 2000).
Name Previous/other names Tissue localization
L-FABP
I-FABP
H-FABP
A-FABP
E-FABP
B-FABP
M-FABP
Z Protein, heme-binding
protein, hepatic FABP
Gut FABP
Muscle FABP
aP2, ALBP
K-FABP, Mal1-1,  KLBP, skin-
FABP, psoriasis-associated-
FABP
BLBP
Myelin P2
Liver, small intestine
Small intestine
Cardiac and skeletal muscle, brain,
mammary gland, kidney, adrenals,
ovaries, testis
Adipocyte, monocyte
Epidermis, adipocyte, mammary tissue,
tongue epithelia, testis
Brain, central nervous system
Peripheral nervous system
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 concentrations in the cytosolic compartments as a whole or more locally near particular
enzymes. In addition, FABPs can exert their action with more specific FABP-membrane
interactions at particular membrane sites. Finally, the FABPs might regulate gene
expression either by a passive maintenance of unbound FA levels as determined by
ligand partitioning, or by a more direct role in cellular targeting of FAs, for example via
direct interaction with nuclear hormone receptors. 
Although studies of binding properties do not directly address a role in cellular
FA trafficking, they nevertheless provide indirect support for such a function by
demonstrating the specificity and affinity of FABPs for FAs. Equilibrium binding
analyses and structural studies clearly demonstrate that most FABPs bind LCFAs (C16-
C20) with high affinity and a molar stoichiometry of 1:1 (Sacchettini et al., 1989;
Sacchettini et al., 1992; Cistola et al., 1989). The exception is L-FABP, which binds not
only LCFAs but also other acyl ligands such as bind other hydrophobic ligands,
including acyl coenzyme A, lysophospholipids, heme and bile salts. (Haunerland et al.,
1984; Vincent and Muller-Eberhard, 1985) The binding charecteristics of L-FABP are
also unique among the FABPs, as this protein can bind a molar ratio of two LCFAs
(Richieri et al., 1994).
The hydrophobic nature of LCFAs complicates the determination of binding
affinities. Therefore, a wide range of different techniques have been utilized to measure
ligand binding. Collectively, these studies are in general agreement concerning the
ligand specificity and binding stoichiometry, but offer widely differing absolute values
for binding affinities. Briefly, methods such as Lipidex and liposome assays have
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generally yielded affinities for LCFAs in the µM range (Glatz and Veerkamp, 1983;
Brecher et al., 1984). More recently, the sensitivity of florescence spectroscopy has led
to the development of several florescence-based assay. As determined by this method,
binding affinities differ for FABP and FA type, with Kd values ranging from 2 to 1000
nM, and in general affinities are higher for saturated vs. polyunsaturated LCFAs
(Richieri et al, 1994). Using the ADIFAB assay, Kd values of H-FABP, L-FABP and I-
FABP for oleate of 10, 9 and 39 nM, respectively are obtained (Richieri et al, 1998).
Affinities of most of the FABPs are generally highest for palmitate, oleate and stereate,
and increased water solubility of polyunsaturated LCFAs is reflected by higher Kd
values (Richieri et al., 1994).
A number of general correlations between the extent of lipid metabolic activity
and the amount of intracellular FABP have also been demonstrated, providing
additional, albeit indirect, support for a LCFA transport and /or trafficking function of
FABPs. For example, there is a correlation between H-FABP content and muscle
development, i.e. a requirement for mitochondrial beta-oxidation (Haunerland et al.,
1993), and induction of peroximal beta-oxidation correlates well with L-FABP levels
(Veerkamp and Moerkerk, 1993).
Among the most generally accepted functions for the FABPs is their
participation in the utilization of dietary lipids. Tissues with high targets of FA
metabolism and uptake/storage, e.g. intestine, liver, adipocyte and muscle, have
increased FABP levels which parallel FA flux and utilization (Glatz and Van der Vussa,
1996). Furthermore, the intestinal distribution of L-FABP and I-FABP, from duodenum
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to colon and crypt to villus tip, correlates well with the known distribution of dietary
lipid uptake and intracellular processing (Cohn et al., 1992). In addition to increasing L-
FABP content, the feeding of high fat diets to rodents results in peroxisomal
proliferation and increased levels of acyl coenzyme-A oxidase, cytochrome P-450 4A1
and peroxisomal beta-oxidation (Isseman et al., 1992).
The numerous links between cellular lipid metabolism and FABP levels,
including PPAR activation, have clearly demonstrated a role for the FABPs in mediating
diverse aspects of lipid utilization, quite possibly via transport mechanisms. To further
understand these roles and to enable the nutritional and/or pharmacological modulation
of FABP function, it is necessary to establish the fundamental mechanisms by which FA
trafficking in cells is modulated by the FABPs.
In addition to the many indirect approaches to an FABP transport function,
several direct approaches have been taken in recent years. In an in vitro system that
measures the flux of oleate through a lipid-water interface was found to increase three
fold (Weisiger et al., 1989). Similarly, L-FABP and H-FABP were reported to increase
the amount and rate of movement radiolabeled fatty acid between two compartments,
although a substantial loss of label to the surface of the apparatus was not accounted for
(Peeters et al., 1989). 
PPAR-alpha is predominantly expressed in tissues with high fatty acid catabolic
rates, such as the liver, kidney, heart and muscle (Kliewer et al., 1999), and ligands for
PPAR- alpha include LCFAs and FA derivatives such as leukotriene B4, as well as the
hyperlipidemic fibrates (Kaikaus et al., 1993). PPAR- alpha activation stimulates FA
catabolism by inducing mitochondrial and peroxisomal beta-oxidation levels, while also
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inducing L-FABP expression (Kaikaus et al., 1993; Isseman et al., 1992). Since
intracellular FA accumulation leads to increased levels of L-FABP, it can therefore be
inferred that L-FABP is probably associated with mitochondrial and peroxisomal beta-
oxidation. It is hypothesized that FABPs promote the effects of LCFAs on gene
transcription and cell growth/differentiation by trafficking ligands directly to the PPARs,
in a manner similar to that proposed for cellular retinoic acid-binding protein (CRABP)
and the retinoic acid receptor (RAR)(Isseman and Green, 1990; Kaikaus et al., 1990).
Such a mechanism implies direct protein-protein interactions between FABPs and
PPARs, which have yet to be demonstrated. Nevertheless, Schachtrup et al., (2004)
speculated that PPARalpha mRNA was absent in the alveolar macrophages although
liver-type FABP was expressed, indicating that gene expression of liver-type FABP was
independent of PPARalpha.
The importance of FABPs in lipid metabolism has also been explored in a more
direct ways by creating knock-out mice models. It has been found that H-FABP null
mice have severe defect LCFA cellular transport and beta-oxidation in cardiac myocytes
(Binas et al., 1999; Schaap et al., 1999). This defect was manifested in the H-FABP null
mice by excercise intolerance, localized cardiac hyperthrophy, and increased myocardial
glucose uptake.
Creation of L-FABP null mice also showed that this protein is important in the
LCFA flux into the cytoplasm, as it is shown that lipogenesis is decreased in the L-
FABP null mice (Martin et al., 2003)
Studies of I-FABP null mice demonstrated that I-FABP is not required for
normal development or dietary fat absorbtion, but there was significant sexual
16
dimorphism in the phenotype (Vassileva et al., 2000). Nevertheless, it should be noted
that mice lacking I-FABP is confounded by substantial compensatory upregulation of
epidermis-FABP (E-FABP), which is normally minimally expressed in wild-type
adipose tissue (Hotamisligil et al., 1996).
FABPs and their relation to LCFAs and glucose metabolism
“The last decade has seen a resurgence of interest in effects of fatty acids on
glucose metabolism” (Randle, 1998). Lipid and glucose metabolism are linked via
substrate competition, hormone signaling, and gene expression (Randle, 1998; Finck et
al., 2002). Patients with uncontrolled diabetes typically have abnormally high levels of
circulating lipids, especially non-esterified fatty acids (NEFA) (Saltiel, 2001). How
elevated NEFAs contribute to the dysregulation of glucose homeostasis, directly impair
insulin sensitivity remains uncertain, but evidence is emerging that muscle might be one
of the direct targets. 
Insulin resistance (IR), the failure to respond to normal circulating
concentrations of insulin, is a common state associated with obesity, aging, sedentary
lifestyle, and genetic predisposition. The failure of insulin to stimulate glucose uptake by
muscle appears to be a primary defect. Also, in certain fat depots, subsequent resistance
to antilipolytic effects of insulin causes increased lipolysis and fatty acid release. These
fatty acids attenuate the ability of insulin to suppress glucose production, but allow a
continual increase in insulin-stimulated fatty acid synthesis. Thus, the dysregulation of
carbohydrate and lipid metabolism accelerates the progression of IR. Beta-cells of the
pancreas normally compensate for the insulin resistant state by increasing basal and
postprandial insulin secretion. This consequently, further aggravates IR. At some point,
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beta-cells can no longer compensate, failing to respond appropriately to glucose. This
ultimately leads to the deterioration of glucose homeostasis and the development of
glucose intolerance, the inability to properly dispose of glucose. Adipose and liver cells
produce more FAs, the liver produces more glucose (gluconeogenesis) in an unregulated
fashion, and the beta-cells undergo progressive decompensation, resulting in the late
stages of disease, where high doses of insulin is required. Approximately, 5-10% of
glucose-intolerant patients progress to frank diabetes.
There are several mechanisms by which plasma fatty acid inhibits glucose
transport activity, leading to the FA-induced IR. Increased plasma free fatty acid
concentrations are typically associated with many IR states, including obesity and type 2
diabetes mellitus (Reaven et al., 1988; Boden et al., 1994; McGarry, 1992).  In a cross-
sectional study of young, normal-weight offspring of type 2 diabetic patients, it has been
found an inverse relationship between fasting plasma fatty acid concentrations and
insulin sensitivity, consistent with the hypothesis that altered fatty acid metabolism
contributes to insulin resistance in patients with type 2 diabetes (Perseghin et al., 1997).
About 40 years ago, Randle et al. (1963) demonstrated that fatty acids compete
with glucose for substrate oxidation in isolated rat heart muscle and rat diaphragm
muscle (Figure I.2). They hypothesized that increased fat oxidation causes the insulin
resistance associated with obesity. The mechanism they proposed to explain the insulin
resistance was that an increase in fatty acids caused an increase in the intramitochondrial
acetyl CoA/CoA and NADH/NAD+ ratios, with subsequent inactivation of pyruvate
dehydrogenase. This in turn would cause intracellular citrate concentrations to increase, 
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Figure I.2: Mechanism of fatty acid–induced insulin resistance in skeletal muscle (as 
proposed by Randle et al.,1963) (top). Potential mechanisms by which plasma fatty acid
inhibits glucose transport activity as proposed by Shulman (bottom). G6P = glucose-6-
phosphate; HK = hexokinase; NAD+ = nicotinamide-adenine dinucleotide; NADH =
reduced nicotinamide-adenine dinucleotide; PDH = pyruvate dehydrogenase; PFK =
phosphofructokinase. (From Shulman G.I. 2000; Perseghin et al., 2003). 
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leading to inhibition of phosphofructokinase, a key rate-controlling enzyme in
glycolysis. Subsequent accumulation of glucose-6-phosphate would inhibit hexokinase II
activity, resulting in an increase in intracellular glucose concentrations and decreased
glucose uptake.  
A recent series of work by Shulman group has challenged this conventional
hypothesis (Roden et al., 1996; Dresner et al.,1999) (Figure I.2). In the first study, the
authors used 13C and 31P NMR spectroscopy to measure skeletal muscle glycogen and
glucose-6-phosphate concentrations in healthy subjects. The subjects were maintained in
euglycemic, hyperinsulinemic conditions with either low or high levels of plasma fatty
acids (Roden et al.,1996). Increasing the plasma fatty acid concentration for 5 hours
caused a reduction of approximately 50% in insulin-stimulated rates of muscle glycogen
synthesis and whole-body glucose oxidation compared to controls. In contrast to the
results from the model of Randle and coworkers, which predicted that fat-induced insulin
resistance would result in an increase in intramuscular glucose-6-phosphate, they found
that the drop in muscle glycogen synthesis was preceded by a fall in intramuscular
glucose-6-phosphate. These data suggest that increases in plasma fatty acid
concentrations initially induce insulin resistance by inhibiting glucose transport or
phosphorylation activity, and that the reduction in muscle glycogen synthesis and
glucose oxidation follows. The reduction in insulin-activated glucose transport and
phosphorylation activity in normal subjects maintained at high plasma fatty acid levels is
similar to that seen in obese individuals (Petersen et al., 1998) and  patients with type 2
diabetes (Rothman et al., 1992).  Moreover, fatty acids seem to interfere with a very
early step in insulin stimulation of GLUT4 transporter activity or hexokinase II activity.
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This conclusion is at odds with the mechanism proposed by Randle et al. (1963) which
predicts an increase in intramuscular glucose-6-phosphate concentrations resulting from
inhibitory effects of fatty acid on phosphofructokinase activity (due to an increase in
intracellular citrate concentration). 
Much research has been published on the effects of LCFA on insulin action.
Increased extracellular fatty acid load can cause acute (Roden et al., 1996) and chronic
(Kim et al., 2001) skeletal muscle IR (reviewed by Petersen and Shulman, 2002).
Likewise, chronically reduced oxidative disposal of fatty acid has been shown to cause
muscle IR (Dobbins et al., 2001), and IR in obesity is associated with reduced oxidative
capacity (reviewed by Kelley and Mandarino, 2000; Kelley et al., 2002). These
situations have in common that they favor the accumulation of lipids such as TGs, fatty
acyl CoA, and DGs. Of these, the latter two are likely, but not certainly, critical in
inhibiting insulin-dependent glucose uptake (Yu et al., 2002). The mechanism of fatty
acid-induced IR is still not causally established and may involve also more than one
mechanism (Thompson et al., 2000; Schmitz-Peiffer, 2002); this is especially true for
the chronic situation. The “lipid oversupply” hypothesis (Kraegen et al., 2001) explains
chronic (skeletal muscle) IR with an accumulation on long chain acyl CoA (LCACoA)
or complex LCFA esters that inhibit insulin signalling (Shulman, 2000) or metabolic
enzymes (Thompson and Cooney, 2000). It is based on the findings that muscle
triglyceride (TG) and LCACoA levels are correlated with IR and that various
manipulations of LCFA metabolism that increase overall lipid supply and/or
esterification produce insulin resistance (Krssak et al., 1999; Dobbins et al., 2001; Kim
et al., 2001).
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Although these situations all favor the accumulation of lipids such as
triglycerides and fatty acyl CoA (Cooney et al., 2002; Kelley et al., 2002), the levels of
triglycerides and LCACoA in muscles are not always correlated with insulin sensitivity
(Straczkowski et al., 2001; Goodpaster et al., 2001; Bruce et al., 2003; An et al., 2004)
and the exact pathways of fatty acid-induced insulin resistance are still being elucidated
(Shulman, 2000; Thompson et al., 2000; Schmitz-Peiffer, 2000; An et al., 2004).  In
addition, sometimes (Storlien et al., 1991; Wilkes et al., 1998), but by far not always
(Kim et al., 2000), it has also been found that basal (insulin-independent) glucose uptake
can be increased due to fat diet, and basal skeletal muscle glucose uptake was increased
in obese patients (Kelley et al., 2002). Voshol et al. (2001) found normal skeletal
muscle, and increased cardiac insulin sensitivity while TG levels were increased in both
organs; nevertheless, other intracellulars were not measured. Skeletal muscle TG levels
were unchanged in rats made insulin-resistant with high-sucrose and high-starch diets
but increased in athletes with increased insulin sensitivity (Straczkowski et al., 2001).
Moreover, PPAR-alpha knockout mice showing decreased FFA oxidation and
accumulation of TG are protected from fat-induced insulin resistance (Guerre-Millo et
al., 2001), although PPAR-alpha agonistics improve insulin sensitivity (Tordjman et al.,
2001)
One of the proposed reasons for muscle IR is an inbalance between the fatty acid
load onto the cell and the cellular capacity to oxidize the load. In otherwise healthy
subjects, both increased extracellular fatty acid concentrations (review, Petersen and
Shulman, 2002) as well as a decreased oxidative capacity of muscle cells (review,
Kelley et al., 2002) can cause IR. 
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Another modifier of insulin sensitivity is muscle contraction (review, Tomas et
al., 2002). Although muscle contraction directly increases availability of GLUT4
transporters, it has a separate effect on insulin-dependent recruitment of GLUT4
transporters. However, the mechanism of this effect is less understood than in case of
LCFA-induced insulin resistance. 
In summary, the links between LCFA and glucose metabolism remain
incompletely understood, especially with regard to LCFA oxidation.  Sometimes
(chronically) decreased LCFA oxidation favors IR, sometimes not. Thus, the oversupply
hypothesis needs additional evidence, ideally through genetic, i.e., causal approaches
and lipid analysis beyond TGs. With H-FABP deficient mice as the model, we rely on a
protein whose expression under normal circumstances is essentially restricted to heart
and skeletal muscle, thus, avoiding difficulties in interpretations that are inherent in
transgenic models (Febbraio et al., 1999) with wider expression patterns. This model
should provide further arguments for or against the over/undersupply hypothesis;
specifically for the role of the ratio of LCFA esterification to oxidation and new insights
into the functions of H-FABP in skeletal muscle LCFA metabolism on glucose
metabolism, to causally relate them with glucose metabolism and insulin action.
The overall objective of this dissertation is to establish the role of H-FABP in the
lipid and glucose metabolism and the role of L-FABP in the LCFA oxidation and
relation to PPAR-alpha in knock-out mice models. No single treatment, pharmacological
or genetic, will cause only one change. For these reasons, it is important to compare
models of altered fatty acid usage with different primary lesions, and to identify the
common denominators. To this end, the dissertation records two primary steps. The first
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chapter documents uses H-FABP mice model to see the effects of H-FABP in the lipid
oxidation and esterification both in the standart diet and high fat diet.  Moreover, insulin
action is evaluated in H-FABP deficient mice kept under healthy (normal diet) and
disease conditions (high fat diet), the latter known to lead to severe whole body and
isolated muscle IR in wild type mice. The second chapter discusses the importance of L-
FABP in hepatic LCFA oxidation in vivo. In addition, this chapter records the
requirement of L-FABP for the action of the transcription factor PPAR-alpha, a master
onswitch for fatty acid oxidation  and a potential target of L-FABP under the conditions
of intense hepatic fatty acid oxidation.
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CHAPTER II
NON-ACUTE EFFECTS OF H-FABP DEFICIENCY ON SKELETAL MUSCLE
GLUCOSE UPTAKE IN VITRO*
Introduction
“Fatty acid overload” due to increased extracellular fatty acid levels (Randle,
1998; Straczkowski et al., 2001; Kim et al., 2001) or pharmacologically reduced fatty
acid oxidation (Dyck and Bonen, 2001) can impair insulin action on skeletal muscle
(review, Petersen and Shulman, 2002), and insulin resistance in obesity was associated
with reduced muscle oxidative capacity (reviews, Kelley and Mandarino, 2000; Kelley
et al., 2002). These situations all favor the accumulation of lipids such as triglycerides
and fatty acyl CoA (Cooney et al., 2002; Kelley et al., 2002). Conversely, genetic
interference with LCFA uptake was shown to prevent fat-induced accumulation of
muscle triglyceride and fatty acyl CoA as well as muscle insulin resistance (Kim et al.,
2004). However, the levels of triglycerides and LCACoA in muscles are not always
correlated with insulin sensitivity (Straczkowski et al., 2001; Goodpaster et al., 2001;
Bruce et al., 2003; An et al., 2004; Han et al., 2004) and the exact pathways of fatty
acid-induced insulin resistance are still being elucidated (Shulman, 2000; Thompson et 
*  Reprinted with permission from Am. J Physiol. “ Non-acute effects of H-FABP deficiency on skeletal
muscle glucose uptake in vitro” by Erol E., Cline G.W., Kim J.K., Taegtmeyer M,, Binas B. 2004. Am J
Physiol (accepted for publication, June, 2004). Copyright @ 2004, the American Physiological Society. 
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al., 2000; Schimitz-Peiffer, 2000, An et al., 2004).  In addition, in some cases
(Straczkowski et al., 2001, Wilkes et al., 1998) it has also been found that basal (insulin-
independent) glucose uptake can be increased due to fat diet, and basal skeletal muscle
glucose uptake was increased in obese patients (Kelley et al., 2002). The LCFA-induced
reduction of insulin sensitive muscle glucose uptake is non-acute, since it is maintained
for a while in the absence of LCFA (e.g., Kim et al., 2000; Thompson et al., 2000);
similarly, any stimulatory effects of LCFA on basal muscle glucose uptake would be
expected to be non-acute, since LCFA oxidation is well known to acutely reduce glucose
oxidation in skeletal muscle (Randle, 1998), an effect that is unlikely to be of
pathogenetic significance (Kelley and Mandarino, 2000; Shulman, 2000). 
Since no pharmacological or genetic treatment can be expected to act at only one
site, it is important to compare models of altered fatty acid usage with different primary
lesions in order to identify the common denominators of glucose uptake. Here we
examined the role of heart-type fatty acid binding protein (H-FABP) in the non-acute
regulation of basal and insulin-stimulated glucose uptake. H-FABP is an important, if
not dominant, LCFA binding protein in heart and skeletal muscle cytosol and is required
for high levels of skeletal muscle LCFA oxidation and esterification at least under
standard diet (Binas et al., 2003). Thus, we were interested to know whether the pool of
LCFA associated with H-FABP would be relevant for the non-acute regulation of
muscle glucose uptake. Accordingly, we measured the glucose uptake into soleus
muscles in vitro after subjecting wild type and H-FABP null mice (Binas et al., 1999) to
either standard or a high fat diet.
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Materials and methods
Mice. Mice lacking the H-FABP gene were originally produced on the
129/Balb/c background (Binas et al., 1999). For the experiments reported here, they
were backcrossed onto the C57/Bl6 background for at least 7 generations, and F1
offspring of heterozygous parents or F1 offspring of null X null and wild type X wild
type crosses were used. If not indicated otherwise, males were used. Mice were
genotyped with a reliable single-tube PCR assay as described (Binas et al., 2003). The
experiments were approved by the University Laboratory Animal Care Committee. 
Diets and starvation. Mice received a standard chow (Harlan Teklad, #8604) or
a high fat diet (Harlan Teklad, #TD 93075, main digestibles in g/kg: 289 protein, 207
starch, 90 sucrose, 274 shortening [Primex], 16 cellulose) for about 4 weeks, or they
were starved overnight (14-16 hours) in cages with fresh bedding. 
Blood metabolite levels. Blood was drawn with heparinized (for plasma) or non-
heparinized (for serum) glass capillaries from tails of overnight-fasted mice. It was
centrifuged immediately to remove blood cells, and the resulting plasma or serum was
kept on ice for metabolite analysis within the next 24 hours. Glucose levels were
measured (Sigma Diagnostics #315) in plasma, and free fatty acid levels were measured
(WACO, #994-75409E) in serum. Before determination of triglyceride (Sigma
Diagnostics #336) and insulin (Chrystal Chem. IL., kit #90060) levels, plasma was kept
frozen (-700C).
Glucose tolerance tests. Mice were starved overnight and injected i.p. with
glucose (20%, 2 mg /g body weight) for determination of tail blood glucose and insulin
at the indicated time points.
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Tissue metabolite levels. Muscle samples were shock frozen and stored at –
80oC. Muscle glycogen concentration was determined essentially as previously
described (Passonneau and Lauderdale, 1974) by digestion in 0.5 ml 1 N KOH,
neutralization with 1 N HCl, treatment of an aliquot (0.1 ml) with 0.5 mg/ml of
amyloglucosidase (Sigma, #A7420), and measurement of the released glucose with
Sigma’s kit # 315. Muscle triglyceride levels were measured with a modification
(Luiken et al., 2003) of a previously described method (Frayn and Maycock, 1980;
Storlien et al., 1991). Levels of LCACoA were determined in shock-frozen tissue
samples as described (Neschen et al., 2002; Yu et al., 2003). 
Deoxyglucose uptake by isolated muscle. Overnight-fasted mice were
anesthetized with Avertin. Soleus muscles were individually incubated in 1.5 ml of
buffer (composition see below) in continuously gassed (5% CO2/95% O2) 20 ml plastic
scintillation vials in a shaking water bath (29ºC). Following the procedure of Etgen et al.
(1999), three-step incubations (each step in a new vial) were performed in Krebs-
Henseleit buffer (KHB)/0.1% bovine serum albumin with the following supplements and
durations: Step 1, 8 mM glucose/32 mM mannitol, 40 minutes; step 2, 40 mM mannitol,
10 min; step 3, 1 mM [3H-]2-deoxyglucose at 0.5 mikroCi/ml (NEN #NET328)/ 39 mM
[U-14C]-mannitol at 0.1 mikroCi/ml (NEN #NEC314), 20 minutes. Insulin (Humulin, Eli
Lilly, #0002-8215-01) was present throughout the incubations at the concentrations
indicated in the main text. Muscles were then blotted on filter paper, trimmed, weighed
and dissolved in 0.1 ml hyamine hydroxide at 600C overnight. 30 mikroliter were
counted in a dual-label liquid scintillation spectrophotometer. Glucose-transport activity
(expressed in micromoles/20 min/g muscle) was calculated by subtracting the
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extracellular from intracellular [3H]-2-deoxyglucose by using the extracellular marker
[U-14C]-mannitol. 
Fatty acid metabolism in isolated soleus muscle. The same setup, but another
incubation medium and time schedule as for the glucose uptake experiments was used.
The incubation medium consisted of KHB, 2% bovine serum albumin (fatty acid-free,
Sigma), 0.1 mM palmitic acid (Sigma), 1 mikroCi/ml of either [3H]-palmitic acid (NEN
#NET043) or [3H]-oleic acid (#NET289), and insulin as indicated. Palmitic acid (125
mM stock in ethanol) was mixed with warmed albumin-containing medium until
completely clear. Freshly excised soleus muscles were incubated for 60 minutes at 290C
and freeze-clamped at the end. Fatty acid oxidation was measured through production of
tritiated water (Dyck and Bonen, 1998) in 1 ml of incubation medium, using a vial
incubated without muscle as blank. Fatty acid esterification into triglycerides was
quantified by homogenization of the muscles with a glass homogenizer in 1 ml ice-cold
chloroform-methanol (1:1), followed by lipid extraction and thin layer chromatography
(8). Bands of main lipid classes were visualized with iodine vapor, scraped out and
counted in 5 ml scintillation liquid (Scintisafe, Fisher Scientific).
Statistical analysis. Data are shown as means ± SE. They were calculated using
GraphPad Prism Statistical software program and analyzed using one way ANOVA
(Bonferroni’s multiple comparison test) and two-tailed Student’s t test, if not otherwise
indicated. Comparisons were made between H-FABP null and wild type mice
(*=p<0.05, **=p<0.01, ***=p<0.001), between standard diet and high fat/high sugar
diet (+=p<0.05, ++=p<0.01, +++=p<0.001), and between incubations in presence or
absence of insulin (#=p<0.05, ## =p<0.01, ###=p<0.001).
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Results
LCFA oxidation in isolated soleus muscles. In the absence of insulin, oxidation
of palmitate was decreased by 53% (Fig. II.1A) in mutant muscles from non-fasted,
chow-fed mice, while oleate oxidation was reduced by 56% (P<0.01, n=5 per genotype).
With this diet, insulin reduced the rate of palmitate oxidation in wild type soleus muscle,
but did not significantly reduce the already lowered rate in H-FABP null muscle (Fig.
II.1A, B). Accordingly, the decrement caused by the mutation was significantly (P<0.05)
larger in the absence of insulin than in its presence. A similar result was found with oleic
acid (not shown). With the high fat diet, the genotype-specific reduction was 67% for
palmitic acid in the absence of insulin (Fig. II.1A), and similar results were obtained
from skeletal muscles of fasted mice (Fig. II.1B) and females (not shown). With this
diet, the insulin-caused reduction of wild type muscle fatty acid oxidation became non-
significant. 
LCFA esterification in isolated soleus muscles. In the absence of insulin,
esterification of palmitate into triglycerides was lower by 26% in null as compared to
wild type muscles from non-fasted, chow-fed mice (Fig. II.1C), while esterification of
oleate was reduced by 38% (P<0.05, n=4 per genotype). With this diet, insulin
moderately but significantly (P<0.05) stimulated palmitate esterification in both
genotypes. With high fat diet, esterification of palmitate was reduced by 33% in null as
compared to wild type muscles (Fig. II.1C); this genotypic reduction occurred on a
lowered level, as the high fat diet reduced the esterification rates in both wild type (-
27%) and null (-34%) muscles. Similar results were obtained with muscles from fasted
30
(Fig. II.1D) and female (not shown) mice. Again, insulin moderately stimulated
palmitate esterification in both genotypes (Fig. II.1C, D). 
Basal deoxyglucose uptake in isolated soleus muscles. Without insulin,
deoxyglucose uptake was lower by ~28% (P<0.05) in isolated soleus muscle from H-
FABP null as compared to wild type mice, regardless of whether the mice had been fed
chow or high fat diet (Fig. II.2A); similar results were seen in female mice (-29% and –
27%, P<0.05) and with extensor digotorum longus (EDL) muscle (-19%, P<0.05) (data
not shown). 
Insulin-stimulated deoxyglucose uptake in isolated soleus muscles. With standard
chow, high levels of insulin (2 mU/ml) increased deoxyglucose uptakes by 4.1
mikromol/mg/20 min (109%) in wild type, and by 4.7 mikromol/mg/20 min (+178.3%)
in H-FABP null samples (Fig. II.2A), but the difference between these increments was
not statistically significant. A similar result was obtained with female mice (data not
shown). The slightly (but not significantly) larger increment in H-FABP null muscles
prompted us to develop a dose response curve. This curve was significantly steeper in H-
FABP null as compared to wild type soleus muscle (Fig. II.2B). As a result, insulin-
dependent deoxyglucose uptake at 0.02 mU/ml insulin was significantly higher in null
vs. wild type soleus muscle (+141%) and approached plateau levels already at 0.2 mU
insulin/ml, but the plateau levels were similar in both genotypes. With the high fat diet,
total deoxyglucose uptake at 2 mU/ml insulin was only non-significantly (+30%)
increased in H-FABP null versus wild type muscle (Fig. II.2A); however, the genotypic
difference of the insulin-dependent increments (Fig. II.2B) was much larger (+190%)
and clearly significant (P<0.01). In the presence of the high insulin concentration, the 
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Figure II.1: Skeletal muscle LCFA oxidation and esterification are impaired in H-FABP
null mice under both standard diet and high fat diet. Isolated soleus muscles from wild type
(white columns) or H-FABP null (black columns) male mice maintained on diets as indicated
were incubated with labeled palmitic acid in the absence (-) or presence (+) of 2 mu/ml insulin as
indicated below the columns. A, palmitic acid oxidation in muscle from mice fed ad libitum; B,
same as A but mice were fasted overnight before sacrifice; C, esterification of palmitate into
triglyceride fraction, mice fed ad libitum; D, same as C but mice were fasted overnight. Each
column represent 6-13 mice. Comparisons were made using one way ANOVA (Bonferroni’s
multiple comparison test) between H-FABP null and wild type mice (*P<0.05, **P<0.01,
***P<0.001), between standard diet and high fat/high sugar diet (+=P<0.05, ++=P<0.01,
+++=P<0.001), and between incubations in presence or absence of insulin(#P<0.05, ##P<0.01,
###P<0.001).
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Figure II.2: Improved insulin action, but reduced basal glucose uptake in isolated H-
FABP null skeletal muscle. A, Male wild type (white columns) and H-FABP null (black
columns) mice were maintained on standard or high fat diet as indicated below columns, fasted
overnight, and then used for isolated soleus muscle incubation in presence of radiolabeled
deoxyglucose and absence (-) or presence (+) of 2 mU/ml insulin. Each column represents 6-10
mice. The unit is 2-dog uptake (nmol/20min/gr). B, Insulin dose response of insulin-dependent
glucose uptake (total minus basal). Male wild type (squares) or H-FABP null (triangles) mice
were used for measurement of deoxyglucose uptake as under A, except that variable insulin
concentrations were added to muscles from mice treated with standard diet. For mice maintained
under high fat diet, only the insulin-dependent uptake at 2 mu/ml is given. Each data point
represents 6-10 mice. *P<0.05, **P<0.01, comparisons between H-FABP null and wild type
mice; #P<0.05, ###P<0.001, comparisons between incubations in presence or absence of insulin;
+++P<0.001, comparison between standard diet and high fat/high sugar diet.
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total rate of deoxyglucose uptake by wild type soleus muscle was significantly reduced
(-43%) by high fat diet, whereas the corresponding reduction with H-FABP null muscle
was smaller (-24%) and not significant at P<0.05 (Fig.II.2A). 
Lipid levels in vivo. With standard diet, the mutation doubled (+97%) plasma
fatty acid levels, but did not affect plasma triglyceride levels (Table II.1), similar to the
phenotype before the backcross (Binas et al., 1999). With high fat diet, circulating fatty
acid levels more than doubled (+117%) in wild type mice, but increased less (+36%) in
H-FABP null mice due to the higher starting level, although the free fatty acid level
remained higher (+24%) than in wild type mice (Table II.1). No genotype-specific
differences were observed in plasma triglyceride levels of mice on a high fat diet,
although triglyceride levels were increased in both genotypes (Table II.1). 
Muscle triglyceride levels remained normal in the H-FABP null mice kept with
the standard diet, but the H-FABP null mutation effectively prevented the almost
threefold increase of muscle triglycerides caused by high fat diet (Fig. II.3A). Total and
individual LCACoA levels in gastrocnemius muscle were not affected by the mutation
with the standard diet, but with the high fat diet, they were moderately reduced (Table
II.2). Statistical significance at P<0.05 was reached for C18:3 (-43%) with the two-tailed
t-test, and for C16:0 (-39%), C18:3 (-43%), and total LCACoA (-26%) with the one-
tailed t-test (Table II.2). LCACoA were also measured in soleus muscles, but statistics
could not be applied because solei had to be pooled (1 muscle per mouse, 7 mice per
pool). The results (2 pools per genotype) showed total LCACoA levels of 23.3 and 27.6
(male wild type) versus 21.5 and 21.2 (male H-FABP null) nmol/g, and 21.1 and 20.1
(female wild type) versus 21.3 and 20.0 (female H-FABP null) nmol/g. Thus, with high
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fat diet there was moderate decrease of muscle LCACoA levels due to the mutation in
males. 
Carbohydrate and insulin levels in vivo. With the standard diet, fasting glucose levels
were decreased by ~25% in male and female H-FABP null vs. wild type mice (Table
II.3). With the high fat diet, glucose levels increased in both wild type (males, +110%;
females, +73%) and H-FABP null (males, +127%; females, +87%) mice, but remained
lower in null vs. wild type mice (males, -19.5%; females, -18%) (Table II.3). Skeletal
muscle glycogen levels were decreased in H-FABP null skeletal muscles by 25% under
standard diet and by 26.5% under high fat diet (Fig. II.3B). Mice maintained on standard
diet did not exhibit a genotype-specific difference of glucose tolerance, but with the high
fat diet (that significantly impaired glucose tolerance in both genotypes), we observed a
moderate yet significant improvement of glucose tolerance in H-FABP null versus wild 
type mice 15 minutes after injection, but not at the later time points (Fig. II.4A). With
the standard diet, fasting insulin levels in H-FABP null mice were significantly
decreased (-66%)compared with wild type levels (Table II.3) (in females the decrease (-
30%) was not significant), but after glucose injection, insulin levels increased faster in
H-FABP null mice than in wild type mice, resulting in identical levels by the end of the
assay (Fig. II.4B). With the fat diet, fasting insulin plasma levels increased by a
comparable factor in wild type (males, +446%; females, +803%) and H-FABP null
(males, +469%; females, +549%) mice, meaning that the insulin levels remained
substantially lower than in the H-FABP null mice (Table II.3). However, unlike after
standard diet, the insulin levels did not increase further during the glucose tolerance test
(Fig. II.4B).
35
Table II.1. Blood levels of free fatty acids and triglycerides in H-FABP null (-/-)
and wild type (+/+) control mice (maintained under either standard chow or 4 weeks of
high fat diet). Mice were fasted overnight before blood sampling. Data are means ± SEM
(n). *P<0.05, **P<0.01, comparisons between genotypes. +P<0.05, ++P<0.01,
comparisons between diets.
FFA (mEq/L) TG (mM) FFA (mEq/L) TG (mM)
Standard diet High fat diet
+/+ 0.37 ± 0.02
(6)
0.10 ± 0.01 (5) 0.80±0.02++ (6) 0.13±0.01+ (6)
-/- 0.73 ± 0.04**
(6)
0.11 ± 0.01 (5) 0.99±0.06*, + (6) 0.14±0.01+(6)
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Table II.2. LCACoA contents (in nmol/g wet tissue) of H-FABP null (-/-) and
wild type control (+/+) gastrocnemius muscles (from mice maintained under either
standard chow or 4 weeks of high fat diet). Data are means ± SD. In brackets, P values
are shown for differences between wild type and H-FABP null samples that are
considered statistically significant according to one tailed (*) and two-tailed (**) t-tests.
Only genotypes, but not diets should be compared, since the diet groups differed by age
and pretreatment (fasted, standard diet; fed, fat diet). 
C16:0 C18:0 C18:1 C18:2 C18:3 Total
Standard diet
Males +/+
n=5 1.70±0.1
7
0.98±0.0
5
4.74±0.40
2.90±0.3
0
1.83±0.23
14.10±1.
30
Males -/-
n=5 1.75±0.1
0
1.16±0.0
8
5.68±0.31
3.20±0.3
8
1.73±0.17
15.21±1.
01
High fat diet
Males +/+
n=7
1.13±
0.2 1.63±0.1
4
4.52±0.47
2.26±0.2
8
1.81±0.28
11.94±1.
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Males -/-
n=7 0.69±0.1
1
1.51±0.0
9
3.50±0.27
1.59±0.1
6
1.03±0.11 
8.84±0.7
3 
Females +/+
n=6 1.11±0.2
0
1.78±0.1
5
4.23±0.41
2.15±0.2
6
2.18±0.53
11.87±1.
75
Females -/-
n=6 0.81±0.0
9
1.85±0.0
9
4.01±0.26
1.99±0.1
8
1.71±0.24
10.94±0.
84
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Table II.3. Blood levels of glucose and insulin in H-FABP null (-/-) and wild
type (+/+) control mice (maintained under either standard chow or 4 weeks of high fat
diet). Mice were fasted overnight before blood sampling. Data are means ± SEM (n).
*P<0.05, **P<0.01, comparisons between genotypes. +P<0.05, ++P<0.01,
+++P<0.001comparisons between diets.
Glucose 
(mM)
Insulin 
(ng/ml)
Glucose 
(mM)
Insulin 
(ng/ml)
Standard diet High fat diet
Males +/+ 7.57±0.32 
(7)
0.29 ± 0.06 
(11)
15.92±0.8+++ 
(6)
1.58 ± 0.15+++
(9)
Males -/- 5.66±0.27*
(7)
0.10 ± 0.03*
(9)
12.82±0.6*,+++ 
(6)
0.57 ± 0.15**,++
(8)
Females +/+ 6.86 ± 0.37 
 (8)
0.18 ± 0.03 
(10)
11.84 ± 0.7+++ 
(6)
1.59 ± 0.49++
 (9)
Females -/- 5.20 ± 0.39*
 (8)
0.12 ± 0.04 
(11)
9.71 ± 0.50*,+++
(6)
0.81 ± 0.28+ 
(11)
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Figure II.3. Triglyceride and glycogen levels in gastrocnemius muscle. Male
wild type (white columns) and H-FABP null (black columns) null mice fed ad libitum
either standard or high fat diet were used (n=6-8 [triglyceride] or 8-10 [glucogen] per
column). Results are given as mean ± SEM. +++=P<0.001, comparisons between diets;
P<0.05,***P<0.001, comparison between genotypes. 
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Fig. II.4. Glucose tolerance and insulin levels. A, Male wild type (triangles) and H-
FABP null (squares) mice maintained under standard diet (empty symbols) or high fat
diet (filled symbols) were fasted overnight and subjected to intraperitoneal glucose
injection (n=8-10 per data point). B, Acute insulin response of male wild type (triangles)
and H-FABP null (squares) mice during glucose tolerance test following standard diet
(empty symbols) and high fat diet (filled symbols). N=4 per data point for 30 and 60
minutes, but n= 8-11 for zero time (see table 3). Results are given as mean ± SEM.
*P<0.05, **P<0.01, comparisons between genotypes.
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Discussion
The present study provides further support for an important role of H-FABP in
muscle LCFA and glucose metabolism. 
First, our data extend our previous result that muscle H-FABP is a major
determinant of myocellular uptake and metabolic availability of palmitate during
standard diet (Binas et al., 2003, Luiken et al., 2003) by adding another fatty acid
(oleate), another diet (high fat diet), and comparing fasting with feeding. At least with
standard chow, LCFA metabolism was reduced without a decrease of total and
individual LCACoA levels, similar to reduced LCFA oxidation, but normal LCACoA
levels, in livers of mice lacking liver FABP (Erol et al., 2004). Further, under nutritional
stress (high fat diet), lack of H-FABP completely prevented the three-fold accumulation
of triglycerides (while reducing LCACoA levels only moderately), adding to our
previous finding that this mutation blunts the contraction-caused decrease of muscle
triglyceride levels (Binas et al., 2003). Thus, H-FABP is a limiting factor for muscle
LCFA metabolism regardless of physiological situation, but more work is needed to
clarify the mechanism leading to altered triglyceride levels in some (contraction, fat diet)
but not other (standard chow) conditions. 
Second, we showed here that FABP is an important mediator of at least some of
the fatty acid effects that reduce muscle insulin sensitivity or responsiveness. Current
thinking (Shulman, 2000;  Schimitz-Peiffer, 2000; Petersen and Shulman, 2002) holds
that relatively slow effects of non-oxidative LCFA metabolites are important in
opposing insulin action. In agreement with this notion, we found that H-FABP null
muscles not only showed increased insulin sensitivity (standard chow) and
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responsiveness (fat diet), but these effects were seen in the absence of added LCFA
(during both preincubation and labeling), making rapid substrate-level competition
between glucose and LCFA oxidation (Randle, 1998) an unlikely explanation. Our
results vary this notion by showing that insulin sensitivity of glucose uptake can be
increased by reduced LCFA binding/metabolism while maintaining normal insulin
responsiveness. It is also of note that LCACoA levels were not affected by the mutation
under this condition (standard chow). With the high fat diet, when insulin-dependent
deoxyglucose uptake by isolated soleus muscle was significantly stimulated by the H-
FABP null mutation even at high (2 mU/ml) levels, we saw only a trend toward
decreased cellular LCACoA levels. Therefore, we suggest that the metabolic availability
of LCACoA (indirectly determined by H-FABP) may be more relevant for insulin
sensitivity or resistance than cellular LCACoA levels. This would fit various recent
observations that a higher insulin sensitivity can be associated with moderate (Houmard
et al., 2002) or no (Bruce et al., 2003; An et al, 2004) decrease of myocellular LCACoA
levels. The H-FABP null mice are a useful model with which to study whether the
metabolic availability of LCACoA or another aspect of LCFA metabolism regulate
insulin-dependent glucose transport. 
Third, we observed that in vitro soleus muscle deoxyglucose uptake was reduced
by the mutation in the absence of insulin, regardless of the nature of prior diet. Thus, at
least in vitro and without added fatty acid, the decreased basal uptake antagonized the
increased insulin sensitivity/responsiveness, thereby reducing the net change of skeletal
muscle glucose uptake. These results resemble our previous observation that glucose
oxidation (measured in the absence of insulin but presence of fatty acid) was decreased
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in soleus muscle isolated from H-FABP null mice fed a standard diet (Binas et al, 2003),
and the decreased basal glycogen synthesis rates (measured in absence of fatty acid) in
isolated soleus muscle from mice lacking the plasma membrane LCFA transporter
CD36, a mutation that at the same time increases the insulin responsiveness of glycogen
synthesis (Hajri et al., 2002). 
Fourth, we found here that blood LCFA levels were increased, and blood glucose
and insulin levels were decreased, in H-FABP null mice. We speculate that hormonal
and substrate conditions in vivo dampen the non-acute genotype-specific changes of
muscle glucose uptake that we observed in vitro. For example, the reduced plasma
insulin levels might limit the effect of the non-acutely increased insulin
sensitivity/responsiveness, while the presence of LCFA might, through the glucose-fatty
acid cycle (Randle, 1998), reduce glucose uptake in wild type muscle more than in H-
FABP null muscle (that oxidize LCFA less efficiently) and thus offset the non-acutely
reduced basal glucose uptake. It may not surprise, then, that glucose tolerance was not
(chow) or only slightly (fat diet) improved in H-FABP null vs. wild type mice. Thus,
both the acute and the non-acute effects of substrate and hormone concentrations will
have to be studied in order to fully understand the role of H-FABP in muscle glucose
uptake in vivo. Such information will also be helpful to understand the energetic impact
of reduced LCFA oxidation in vivo that involves reduced soleus muscle ATP and
phosphocreatine levels, but not a reduced mitochondrial enzyme capacity (Binas et al.,
2003). 
In conclusion, we have described here two non-acute and opposite effects of H-
FABP on muscle glucose uptake. Our results are compatible with the view that lipid
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pools determined by H-FABP are more important for regulating basal and insulin-
dependent skeletal muscle glucose uptake than total cellular lipid levels.
     
44
CHAPTER III
LIVER FATTY ACID BINDING PROTEIN IS REQUIRED FOR HIGH RATES
OF FATTY ACID OXIDATION BUT NOT FOR THE ACTION OF PPAR-
ALPHA IN FASTING MICE*
 Introduction
Liver fatty acid binding protein (L-FABP), a member of the genetically related
cytosolic FABP family (Mc Arthur et al., 1999; Hertzel and Bernlohr, 2000; Storch and
Thumser, 2000), is expressed in the liver, and together with other FABPs in intestine
and kidney. Its main known molecular function is the reversible binding of hydrophobic
ligands, including long-chain fatty acids (LCFA), LCFA-CoA, phospholipids,
peroxisome L proliferators, and others (Mc Arthur et al., 1999; Hertzel and Bernlohr,
2000; Storch and Thumser, 2000; Haunerland et al., 1984; Wolfrum et al., 2000). The
abundance (reaching 2.5% of cytosolic protein) and correlation of its levels with the
extent of LCFA metabolism in vivo (Ockner et al., 1979; Hung et al., 2003) suggest that
L-FABP is important in hepatic LCFA metabolism. In line with this, numerous
alterations of LCFA metabolism have been observed in cell lines transfected with L-
FABP cDNA (Mc Arthur et al., 1999), notably in the context of the present study 
* Reprinted with permission from FASEB J “ Liver fatty acid-binding protein is required for high rates of
fatty acid oxidation but not for the action of PPAR-alpha in fasting mice” by Erol E., Kumar L.S., Cline
G.W., Shulman G.I., Kelly D.P., Binas B. 2004. FASEB J 2004 18(2):347-9. Copyright © 2004, The
FASEB Journal Online by The Federation of American Societies for Experimental Biology.
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increases in LCFA uptake (Murphy et al., 1996) and oxidation (Linden et al., 2002), 
whereas an L-FABP antisense cDNA inhibited LCFA uptake (Wolfrum et al., 1999).
However, because these cell lines were poorly differentiated, it is not clear whether the
results apply to the metabolically highly active, fully differentiated hepatocyte.
Moreover, the mechanisms underlying the potential roles of L-FABP in LCFA
metabolism remain unclear.
Several observations are consistent with a substrate-level role of L-FABP.
Displacement of the fluorescent LCFA analog NBD-stearate from L-FABP by alpha-
bromopalmitate was accompanied by reduced cytoplasmic diffusion of NBD-stearate
(Luxon, 1996). Cytoplasmic diffusion of NBD-stearate was also reduced in
permeabilized hepatocytes, but restored by addition of L-FABP (Kaikaus et al., 1993).
Furthermore, L-FABP modulated ligand transfer and metabolism in cell-free systems
(Mc Arthur et al., 1999; Storch and Thumser, 2000). Finally, hepatic L-FABP levels are
boosted by peroxisome proliferators (Kaikaus et al., 1993; Lee et al., 1995) and reduced
in peroxisome proliferator-activated receptor alpha (PPAR-alpha) null mice (Kersten et
al., 1999), consistent with the idea that L-FABP itself might be part of the lipid
oxidation machinery. Thus, L-FABP might modulate the availability of its ligands for
metabolism by raising their cytosolic concentration, sequestering them, and facilitating
their intracellular movement. More recently, the possibility that L-FABP affects LCFA
metabolism by increasing the activity or level of the transcription factor PPAR-α has
caused great interest. L-FABP and PPAR-alpha exhibit a similar ligand binding
spectrum (compare ref Corton et al., 2000 with ref Wolfrum et al., 2000 and references
therein). LFABP can be found in the nucleus (Bordewick et al., 1989) and physically
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interacts with PPAR-alpha (Wolfrum et al., 2001). L-FABP ligands added to cultured
hepatoma cells stimulate transcription of a reporter gene carrying a peroxisome
proliferator-responsive element, in strict correlation with the endogenous content of L-
FABP (Wolfrum et al., 2001). Finally, overexpression of L-FABP in L cells increases
nuclear fatty acid uptake (Huang et al., 2002). Thus, L-FABP might stimulate the
intrinsic activity of PPAR-alpha Moreover, it might increase PPAR-alpha levels, because
transfection of L-FABP cDNA into hepatoma cells increased the levels of PPAR-alpha
mRNA (Linden et al., 2002). It was suggested (Wolfrum et al., 2001) that L-FABP is the
gateway of hydrophobic compounds to gene transcription, and this concept was most
recently extended to three other members of the FABP gene family, heart-type,
adipocyte, and keratinocyte FABP (Huang et al., 2002).
Taken together, the literature suggests substantial roles for L-FABP in LCFA
metabolism both by modulating availability of substrates as well as by increasing
enzymatic capacity throughactivation of PPAR-alpha and possibly other transcription
factors. Here, we used the recently created L-FABP null mice (Martin et al., 2003) to
study the role of L-FABP in hepatic LCFA oxidation and the potential involvement of
PPAR-alpha.
Materials and methods
Mice. The creation of mice lacking the L-FABP gene (L-FABP null mice) has
been described previously (Martin et al., 2003). The mutation was backcrossed onto the
C57/Bl6 (Harlan, Madison, WI) background for two to three (Fig. 1.3, Table 2) or four
generations (Table 1). PPAR- alpha null mice (Lee et al., 1995) were backcrossed for six
generations onto the C57/Bl6 (Jackson, Bar Harbor, ME) background. Experimental L-
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FABP null and PPAR- alpha null mice and their respective wild-type controls were
derived from heterozygous intercrosses. Mice were used at the age of 3.6 months (Fig.
1-3, Table 2) or 2-3 months (Table 1). In each physiological situation represented in a
given figure or table, null and wild-type mice of the same sex were exactly matched for
backcross generation and age (less than 2 weeks difference). However, animal groups
studied under different physiological situations differed by age and backcross within the
segments given above. In comparisons of PPAR- alpha null and L-FABP null mice, all
mice (including the wild-type controls) were treated identically and simultaneously.
Animal experiments were approved by the University Lab Animal Care Committee.
Diets and starvation. Mice were fed either a standard chow (#8604, Harlan
Teklad; 3.24 kcal/g [57.6% from CHO,12.2% from fat, 30.2% from protein]), a
ketogenic diet for 3 days (#TD 96355, Harlan Teklad; 6.69 kcal/g [0.3% from CHO,
90.7% from fat, 9.0% from protein]; main digestibles in g/kg: 586 shortening [Crisco],
86 corn oil, 151 protein, 5.4 carbohydrate), or a diabetogenic diet for ~4 weeks (#TD
93075, Harlan Teklad; 4.80 kcal/g [24.0% from CHO, 55.0% from fat, 21.0% from
protein]; main digestibles in g/kg: 289 protein, 207 starch, 90 sucrose, 274 shortening
[Primex], 16 cellulose). Alternatively, mice were starved overnight (14-16 h) in cages
with fresh bedding.
Determination of blood metabolites. Tail blood was drawn from conscious
mice in most cases, but in a few cases, blood was obtained by cardiac puncture under
Avertin. Serum was kept at 4°C and used within 24 hours for measurement of
nonesterified fatty acids (NEFA) (#994-75409E, Wako Diagnostics, Richmond VA),
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triacylglycerol (#336, Sigma, St. Louis, MO), β-hydroxybutyrate (BHB; #310UV,
Sigma), and glucose (#315, Sigma).
Octanoate challenge. Sodium octanoate (500 mM, in 0.9% NaCl) was injected
intraperitoneally at 6 mikroliter per gram of body weight into mice starved overnight. At
the indicated times, aliquots of 10 mikroliter of tail blood were withdrawn for analysis
of ΒΗΒ. 
Determination of long-chain acyl CoA.  Liver pieces from mice starved
overnigh were shock-frozen with liquid nitrogen, weighed, powdered, and processed as
previously described (Neschen et al., 2002).
Measurement of fatty acid oxidation in isolated hepatocytes. Primary
hepatocytes were obtained by an established method (Madden et al., 2000) with
modifications. In brief, mice were anesthetized with Avertin, and each liver was
perfused through the V. cava inferior with two consecutive solutions (prewarmed to
37°C): first, with Ca/Mg-free Earle.s balanced salt solution/0.5 mM EGTA (perfused for
4.6 min at 7.8 ml/min), and second with HEPES-buffered Hanks balanced salt solution
(#24020-117, Gibco-BRL, Gaithersburg, MD) containing 0.3 mg/ml collagenase D
(#17103-011, Gibco-BRL) (perfused for 6.8 min at 8.10 ml/min). Hepatocytes were
released into Dulbecco.s modified Eagle.s medium (DMEM), filtered, and centrifuged at
600 rpm for 2 minutes, followed by centrifugation in 50 vol/% each of DMEM (with
10% FBS) and of Percoll (with Hanks salts). The pellet was washed two times with
serum-free DMEM. Cell viability, determined by trypan blue exclusion, always
exceeded 95%. Hepatocytes (500,000 cells in a final vol of 1 ml) were incubated
(duplicate for each mouse) for 1 h at 37°C with agitation under an atmosphere of 5%
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CO2/95% O2 in sealed glass vials in Krebs-Henseleit bicarbonate buffer supplemented
with 1 mM carnitine (Sigma), 2% (w/v) fatty acid-free bovine serum albumin (BSA)
(Sigma), 1 mM palmitate (Sigma), and 0.5 mikroCi/ml [1-14C]-palmitate (#P- 8575,
Sigma). The fatty acid (0.4 M stock in ethanol) was completely dissolved by prewarming
the buffer at 37°C before adding the cells. At the end of incubation, 30 µl of the
suspension were removed onto ice for later enzymatic measurement of ΒΗΒ, a tube with
0.2 ml hyamine (ICN Radiochemicals, Irvine, CA) was inserted, the vial was sealed
again, and 0.3 ml of 3 M perchloric acid was injected into the cell suspension. After
incubation for 90 minutes at 4°C, the acid incubation mixture was centrifuged for 5
minutes at 6000 rpm and the supernatant as well as the hyamine sample were subjected
to liquid scintillation counting (Scintisafe, Fisher Scientific, Pittsburgh, PA). The rates of
palmitate oxidation were calculated as the sum of trapped 14CO2 (hyamine sample) and
14C-labeled acid soluble products (supernatant). BHB was determined with Autokit
3HB (Wako Diagnostics, Richmond, VA) after removing the cells (4°C, 2 minutes, 5000
rpm).
Measurement of fatty acid oxidation in liver homogenates. Guided by a
published protocol (Veerkamp et al., 1986), we determined palmitate oxidation rates in
duplicates per mouse. In brief, fresh liver pieces were homogenized at 5% (wt/vol) in
ice-cold buffer (10 Mm Tris-HCl, pH 7.4, 2 mM Na2-EDTA, 0.25 M sucrose) with a
tight-fitting Dounce homogenizer. 25 mikroliter of liver homogenate were added to 475
µl of assay buffer containing 75 mM Tris-HCl (pH 7.2), 10 mM K2HPO4, 1 mM
EDTA, 5 mM MgCl2, 0.5 mM L-carnitine, 25 mikroM cytochrome c, 0.1 mM CoA, 25
mM sucrose, 5 mM ATP, 0.5 mM malate, and 1 mM NAD. After preincubation for 30
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minutes at 37°C and agitation, palmitate was added to a final concentration of 1 mM (1
mikroCi/ml) palmitate/2% fatty acid-free BSA, and incubation was continued for
another 30 minutes. BHB and radiolabeled oxidation products were determined as
described for the hepatocyte incubations.
Northern blotting. Total liver RNA was isolated with RNAwiz (Ambion,
Austin, TX) and separated at 20 mikrogram/lane on 1% agarose/formaldehyde gels.
Northern blotting was performed according to standard methods (Sambrook and Russell,
2001), using BrightStar-Plus membranes, ULTRAhyb buffer, and the Strip-EZ DNA kit
(Ambion). Manufacturer.s instructions were followed except that washing was
performed at 60°C. The probes (26.29) used were cDNAs encoding medium-chain acyl
CoA dehydrogenase (MCAD), liver carnitine palmitoyltransferase 1 (L-CPT1),
cytochrome P4504A3 (CYP4A3), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and PPAR-alpha (26), long-chain acyl CoA dehydrogenase (LCAD) (27),
mitochondrial hydroxymethyl glutaryl (HMG) CoA synthase (28), and L-FABP (29).
Signals were visualized with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA),
quantified with ImageQuant software, and normalized to the signal of GAPDH mRNA.
Data evaluation. Data were evaluated with statistics software (GraphPad Prizm,
San Diego, CA). Error bars represent the standard errors of the mean. Differences
between wild-type and null groups were analyzed by Student’s t test at the 95%
confidence level.
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Results
The ketone body ΒΗΒ is an end product of hepatic fatty acid oxidation (McGarry and
Foster, 1980), and its plasma levels are often used to assess hepatic fatty acid oxidation
in vivo (see Kersten et al., 1999 and Leone et al., 1999). Accordingly, we measured
plasma hydroxybutyrate levels in L-FABP null mice in order to obtain an indication for
potentially altered LCFA oxidation. Wild-type and L-FABP null mice were subjected to
standard diet (a nonketogenic condition), to starvation (a ketogenic condition), to a short
term high-fat, low-sugar diet (another ketogenic condition), and to a chronic highfat/
sugar (diabetogenic) diet, followed or not followed by starvation. Body weights were not
affected by the genotype under these nutritional conditions at the time point of metabolic
assays (results not shown). As shown in Figure III.1A, steady-state levels of blood ΒΗΒ
were significantly reduced in null vs. wild-type female mice under all ketogenic
conditions (ketogenic diet and starvation irrespective of type of prior diet), whereas
under nonstarving conditions (standard or diabetogenic diet), no significant ketogenesis
occurred in either genotype. Similar results were obtained in male mice, but unlike in
females, the genotypic difference in ΒΗΒ levels was further increased by long-term
diabetogenic diet before the starvation. Figure III.1B shows that in contrast to ΒΗΒ
levels, levels of circulating NEFA were not reduced under any ketogenic or
nonketogenic condition. Rather, NEFA levels tended to increase; this was not
statistically significant during starvation but reached significance under all other
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Figure III.1. A liver-intrinsic defect impairs hepatic long chain, but not medium chain, fatty
acid oxidation in LFABP null mice. Serum levels of beta-hydroxybutyrate (A) and NEFA (B)
were measured in female (left panels) and male (right panels) mice subjected to starvation
(overnight), standard diet, ketogenic diet (3 days), or diabetogenic diet (4 wk). Black columns,
wild type; white columns, L-FABP null. Each column pair represents mice that were matched for
age, sex, and backcross generation, but mice represented by different column pairs may slightly
differ by age and backcross generation. Each column includes 3 experiments with 2 mice each
per genotype (n=6 total per genotype), except for free fatty acid measurements in starved and
standard diet-fed mice where each column represents 2 experiments with 3 mice each (females,
n=6 per genotype total) or 3 and 2 mice each (males, n=5 per genotype total). *P<0.05;
**P<0.01, ***P<0.001; comparisons between genotypes. C) Octanoate injection restores
ketogenesis in L-FABP null, but not PPARa null, mice. L-FABP null mice (L–/–, empty circles;
n=5) and their wild-type litter mates (L+/+, filled circles; n=5) as well as PPARa null mice (P–/–
, empty triangles; n=4) and their wild-type litter mates (P+/+, filled triangles; n=4) were injected
with octanoic acid, and plasma beta-hydroxybuturate levels were determined at the indicated
time points. All mice were females. Error bars (SE) did not exceed symbol sizes.
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Figure III.2. Expression of key genes of lipid oxidation in L-FABP null and PPARa null livers.
Shown are representative Northern blots prepared from mice starved overnight (14–16 h) (A)
and mice fed standard chow (B). L, LFABP; P, PPARa; +/+, wild type; –/–, null. Separate
matched wild-type controls were used for the L and P mice. For each genotype, two samples
from two different mice were applied to neighboring lanes on the gel. All mice were females. A,
B) Representation of two blots that were each hybridized multiple times. Identical results were
obtained with a second pair of Northern blots not shown that were prepared with RNA samples
from additional mice, resulting in 4 analyzed mice for each of the 4 groups of mice. C)
Quantification of expression levels in starved mice. D) Quantification of expression levels in fed
mice (except for CYP4A3 because of low levels). Signals of all bands of all blots were
normalized to the respective GAPDH signals, and the resulting numbers from null mice were
divided by those from wild-type control mice. White columns, (L–/–)/(L+/+) ratio; black
columns, (P–/–)/(P+/+) ratio. *P < 0.05; **P < 0.01; ***P < 0.001; comparison between null
and wild type. †Ratio equals zero by definition.
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conditions in females. In males, the increase was seen only after long-term diabetogenic
diet (Fig. III.1-B). The above results suggest that hepatic fatty acid oxidation is reduced
in L-FABP null mice and that this reduction is not due to decreased substrate provision
to the liver. To determine conclusively whether the decreased ΒΗΒ levels are due to an
intrahepatic defect, we isolated primary hepatocytes and incubated them with palmitate.
Table III.1 shows that freshly isolated hepatocytes from L-FABP null mice produced
significantly less ΒΗΒ than those from wild-type mice. In parallel, total fatty acid
oxidation was determined as the sum of radiolabeled carbon dioxide and radiolabeled
acid-soluble products released. Again, a reduction was seen in the L-FABP null variant,
similar in extent to the reduction of ΒΗΒ (Table III.1).
Taken together, the above results demonstrate that hepatic fatty acid oxidation is
impaired in the absence of L-FABP and that the reduction is due, at least in part, to an
intrahepatic defect. A potential explanation for the reduced fatty acid oxidation and
ketogenesis in L-FABP null mice might be decreased intracellular substrate levels. We
therefore measured levels of LCFA-CoA, the direct substrates for β oxidation. As shown
in Table III.2, a trend for increased stearoyl-CoA (C18:0) and decreased linoleoyl-CoA
(C18:2) levels was seen in both females and males, but only for stearoyl-CoA in females
was statistical significance reached at P<0.05. However, levels of palmitoyl-CoA
(C16:0) were not changed despite the significant reduction in palmitic acid oxidation;
moreover, total LCFA-CoA levels, defined here as the sum of all C16 and C18
LCFACoAs, were clearly unaltered. The essentially normal LCFA-CoA levels do not 
rule out their reduced availability. However, because L-FABP is able to increase the
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Table III.1. Fatty acid oxidation in isolated liver tissue.
 a: For each experiment, a wild-type (+/+) and an L-FABP null (–/–) mouse (both
female) were starved overnight and then used to obtain either intact hepatocytes (six
independent experiments total) or liver homogenates (four independent experiments
total). After incubating duplicate aliquots of the cells or homogenates with 1 mM
radiolabeled palmitate, we determined labeled oxidation products (nmol/h/500,000 cells
or nmol/min/g wet liver) and beta-hydroxybutyrate concentrations (mikromolar). ASP,
acid-soluble products. For experimental details, see Materials and Methods. Results are
given as mean ± SE. *P < 0.05; **P < 0.003 null vs. wild type. Comparisons were made
by Student’s t test.
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Table III.2. Profile of LCFA-CoA in livers of wild-type and L-FABP null mice.
Female (F) and male (M) wild-type (+/+) and L-FABP null (–/–) mice were starved
overnight. LCFA CoA levels (nmol/g) are given as mean ± SE, numbers (n) of analyzed
mice are given in brackets. *P < 0.05 null vs. wild type.
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activity (Wolfrum et al., 2001) and levels (Linden et al., 2002) of PPAR-alpha, a
transcription factor that is required for a high capacity of ketogenesis (Kersten et al., 
1999; Leone et al., 1999; Le May et al., 2000), it seemed possible that the capacity for
ketogenesis was reduced in L-FABP null mice. Three approaches were taken to assess
the capacity for fatty acid oxidation and ketogenesis.
First, we tested whether ketogenesis in L-FABP null mice can be restored with
octanoic acid. This fatty acid is a good substrate for ketogenesis in wild-type
hepatocytes, but it is not a physiologically significant primary substrate of ketogenesis,
not a ligand of L-FABP, and not efficiently metabolized by isolated PPAR-α null
hepatocytes (Le May et al., 2000). Octanoic acid was injected intraperitoneally into
starved wild-type, L-FABP null, and PPAR-alpha null mice, and ketogenesis was
followed over 6 h thereafter. Figure III.1C shows that after octanoate injection, a
massive increase in ketogenesis occurred in both wild-type and L-FABP null mice. The
resulting peak ΒΗΒ levels were comparable between wild-type and L-FABP null mice
even though the null mice had started from a much lower level and were much higher
than achievable in any physiological condition, indicating similar capacities for
ketogenesis. In contrast, the PPAR-alpha null mice that also exhibited low starting ΒΗΒ
levels were unable to raise these levels significantly after octanoic acid injection (Fig.
III.1C). These results suggest that the effect of LFABP deficiency on ketogenesis is
restricted to primary substrates that are ligands of L-FABP.
Second, as a composite enzymatic assay that assesses all steps of LCFA
oxidation except substrate provision, we measured the oxidation of albumin-bound
palmitic acid in liver homogenates. As shown in Table III.1, no difference in either ΒΗΒ
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production or radioactive palmitate oxidation was seen between L-FABP null and wild-
type homogenates. This suggests that the effect of L-FABP deficiency on LCFA
oxidation originates on the level of intracellular substrate availability rather then
oxidative capacity.
Third, the expression of key genes of lipid oxidation was compared between L-
FABP null, PPAR- alpha null, and wild-type mice. Figure III.2A shows that compared
with wild-type litter mates, starving PPAR- alpha null mice showed significantly
reduced levels of mRNAs encoding CYP4A3, MCAD, ACO, mitochondrial HMG CoA
synthase, and L-FABP, whereas mRNAs encoding LCPT1 and LCAD showed little or
no reduction. These results are quantified in Figure III.2C, giving the ratios of null to
wild-type levels. The expression of LCAD has not been previously measured in the
PPAR- alpha null mice, but all other results agree with published findings (Kersten et
al., 1999; Leone et al., 1999; LeMay et al., 2000). The published decrease of
mitochondrial HMG CoA synthase mRNA was more dramatic, however, perhaps
because Le May et al. (2000) starved their mice longer (24 hours) than we did (14-16
hours). More importantly, Figure III.2A and III.2C further show that none of the above
mRNAs (except L-FABP) was changed in L-FABP null vs. wild-type livers; moreover,
absence of L-FABP did not affect levels of PPAR- alpha mRNA.When the Northern
blotting experiments were repeated under feeding (standard diet), a similar tendency to
reduced gene expression was seen in PPAR- alpha null mice (Fig. III.2B, 2D), again in
agreement with literature, although we found a somewhat smaller genotypic difference
in HMG CoA synthase than Le May et al. (2000) and a larger difference in L-FABP
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Figure III.3. Effect of L-FABP deficiency on circulating triacylglycerol and glucose
levels. Blood samples were taken from mice subjected to starvation (overnight), standard
diet, ketogenic diet (3 days), diabetogenic diet (4 wk), and diabetogenic diet plus
starvation. Levels of triglycerides (triacylglycerols) (A) and glucose (B) were determined
in female mice (left panels) and male mice (right panels). Black columns, wild type;
white columns, L-FABP null. Each column includes 3 experiments with 2 mice each per
genotype (n=6 total per genotype). Each column pair represents mice that were matched
for age, sex, and backcross generation, but mice represented by different column pairs
may slightly differ by age and backcross generation. ***P<0.001; comparisons between
genotypes.
60
mRNAs than Kersten et al. (1999). Again, in contrast with PPAR- alpha null mice, no
significant genotypic difference was seen in L-FABP null mice for most of the above
mRNAs. Unexpectedly, however, a significant reduction of mitochondrial HMG CoA
synthase mRNA was seen in all fed L-FABP null mice, and there was a similar tendency
with L-CPT1 that did not reach significance (Fig. III.2B, 2D).
Finally, we measured two more plasma metabolites in order to probe the broader
impact of the L-FABP null mutation on body fuel metabolism. As shown in Figure
III.3A, plasma triacylglycerol levels remained normal under standard diet, starvation,
and ketogenic diet. Interestingly, however, they were significantly increased in the
plasma of L-FABP null mice after long-term diabetogenic diet (Fig. III.3A). No
differences between wild-type and L-FABP plasma glucose levels were seen under any
condition (Fig. III.3B).
Discussion
To assess the physiological significance of L-FABP, we recently produced L-
FABP null mice. Using these mice, we demonstrated a major contribution of L-FABP to
cytosolic fatty acid binding capacity of the liver; other FABPs did not compensate for
this function (Martin et al., 2003). The present study was designed to answer the
following two related questions. First, Is L-FABP important for hepatic LCFA oxidation
in vivo? Second, Under conditions of intense hepatic fatty acid oxidation, is L-FABP
required for the action of the transcription factor PPAR- alpha, a master onswitch of
fatty acid oxidation (Kersten et al., 1999; Leone et al., 1999) and a potential target of L-
FABP (Wolfrum et al., 2001). The results presented herein answer the first question to
the affirmative, but strongly argue against the second possibility.
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The present study revealed a significant role of L-FABP in hepatic LCFA
oxidation, as concluded from the reduced LCFA oxidation and ΒΗΒ production in
isolated L-FABP null hepatocytes, which is in line with reduced ΒΗΒ levels seen in
blood plasma of L-FABP null mice. However, the effect did not exceed 35% in vitro
(Table III.1), whereas at comparable fatty acid concentrations in vivo (Fig. III.1B), it
approached and sometimes exceeded 50% (Fig. III.1A). The reasons for this discrepancy
may include shortcomings of the in vitro model or extrahepatic components of the
phenotype, but they are unlikely to include a reduced provision of substrate (NEFA) to
the liver. Indeed, compared with wild-type mice, plasma NEFA levels were
nonsignificantly increased in female L-FABP null mice during starvation following
standard diet but were significantly increased under ketogenic diet and starvation after
diabetogenic diet, as might be expected when fatty acid oxidation is inhibited in a major
organ. Also note that the phenotype of reduced fatty acid oxidation in L-FABP null mice
appeared to vary with gender.
 In line with the known fact that long-term high-fat diet raises L-FABP
expression in males to female levels (Kersten et al., 1999), male L-FABP null mice
showed the largest decrement in ketogenesis during starvation following a long-term
diabetogenic diet, whereas no such trend was seen in the females. Similarly, plasma
NEFA levels of male L-FABP null vs. wild-type mice were significantly increased only
under starvation following the diabetogenic diet, whereas the increase was significant in
females also under most other nutritional conditions.
Taken together, our results show that the blunted fatty acid oxidation and
ketogenesis is, at least in part, of intrahepatic origin, demonstrating that L-FABP is a
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cell-intrinsic stimulator of LCFA oxidation. The increase in plasma fatty acid levels
under some ketogenic conditions also implies that LFABP impacts whole body lipid
metabolism, a conclusion that can be extended to nonketogenic conditions. Both plasma
NEFA and triacylglycerols were increased in (at least female) L-FABP null mice after
chronic diabetogenic diet (without starvation), conceivably due to reduced hepatic
clearance. The mechanisms underlying the altered plasma levels in nonketogenic
conditions clearly deserve further investigation.
The second question addressed here concerns the mechanism by which L-FABP
stimulates LCFA oxidation. Although the high cytoplasmic concentration of L-FABP in
fully differentiated hepatocytes is suggestive of a substrate-level function, L-FABP
concentrations were recently shown to limit the activity of the lipid-dependent
transcription factor PPAR- alpha in PPAR- alpha - transfected cells (Wolfrum et al.,
2001). This suggested to us that transcription of PPAR- alpha target genes and
consequently the capacity for fatty acid oxidation might be compromised in the absence
of LFABP.
Ketogenesis from endogenous substrates is severely impaired in both PPAR-
alpha null mice (Kersten et al., 1999; Leone et al., 1999 and present study) and L-FABP
null mice (present study). However, we found that ketogenesis from medium-chain fatty
acid (octanoate) is reduced only in PPAR- alpha null mice, whereas octanoate boosted
ketogenesis in L-FABP null mice to levels higher than achievable in wild-type mice by
fat diet or starvation, showing that the capacity for ketogenesis was fully maintained.
This difference in ketogenic capacity can be explained by differences in gene
expression.
63
In agreement with literature (Leone et al., 1999; Le May et al., 2000), we found
that upon starvation, levels of the mRNAs encoding MCAD and mitochondrial HMG
CoA synthase were reduced in the PPAR- alpha null vs. wild-type mice. In contrast,
they were normal in the L-FABP null mice. Thus, at least some PPAR- alpha target
genes and the associated biochemical process were not affected in starving LFABP null
mice. Two other PPAR- alpha target genes, ACO and CYP4A3, representing
peroxisomal and microsomal lipid oxidation, respectively, were also expressed
normally, suggesting that PPAR- alpha -dependent gene transcription was generally
unaffected in the starving L-FABP null mice investigated. In line with this, PPAR- alpha
mRNA levels were also normal. Finally, the normal levels of the mRNAs encoding
LCAD and L-CPT1 suggest that reduced hepatic LCFA oxidation in the starving L-
FABP null mice was not caused by altered gene expression through PPAR- alpha -
independent gene transcription either. In agreement with this conclusion, we did not find
a reduced rate of palmitic acid oxidation in liver homogenates of L-FABP null mice,
arguing that the levels of all enzymes involved in LCFA oxidation and ketogenesis are
maintained. In fact, because the principal difference between intact isolated hepatocytes
and liver homogenates is that in the latter, plasma membranes are disrupted and the
oxidative substrate is bound by another carrier (albumin), the oxidation defect is most
likely at the level of intracellular substrate provision.
Taken together, our data do not support a role for L-FABP in PPAR- alpha
function or indeed gene expression in general under starvation conditions in vivo. In this
respect, we note that similar to L-FABP null hepatocytes, H-FABP null cardiomyocytes
lack compensatory FABP expression, show substantially reduced LCFA oxidation
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(while maintaining normal oxidative capacity), and oxidize octanoic acid normally
(Schaab  et al., 1999). In contrast, octanoic acid oxidation is significantly impaired in
PPAR-α null hearts (Watanabe et al., 2000).
In apparent contradiction with the above results, Wolfrum et al. (2001) and Tan
et al. (2002) convincingly demonstrated that L-FABP and H-FABP are able to activate
PPAR- alpha in hepatoma and COS cells, respectively. Further, Tan et al. (2002) also
demonstrated activations of transfected PPAR-beta and -gamma by keratinocyte and
adipocyte FABP, respectively, suggesting that PPAR activation is a general feature of
the FABP family. We suspect that the solution of this contradiction may be the level of
lipid flux in the cells concerned. The cell lines used by Wolfrum et al. and Tan et al.
exhibit a low degree of differentiation that probably cannot support high LCFA fluxes,
and low endogenous PPAR- alpha levels that were actually raised by transfection.
Importantly, Tan et al. (2002) showed that transfected keratinocyte FABP activates
endogenous (nontransfected) PPAR-beta only at extremely low ligand levels. Thus, in
vivo, FABPs may be important for the action of cognate PPARs only under conditions
of low lipid metabolism, such as during onset of differentiation.
In contrast, at least in starved differentiated hepatocytes (present study) and
cardiomyocytes (Schaab et al., 1999; Binas et al., 1999), LCFA fluxes seem to remain
high enough to fully activate PPAR- alpha even in the absence of FABPs. In this
context, our observation of a reduction of mitochondrial HMG CoA synthase mRNA
levels in the L-FABP null liver under standard diet may be of interest. This decrease
occurred also in the PPAR- alpha null mice. However, under the same condition, MCAD
gene expression was clearly not reduced in the L-FABP null mice, whereas it was
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substantially reduced in the PPAR- alpha null mice. Thus, PPAR- alpha -independent
mechanisms might contribute to the reduced expression of HMG CoA synthase under
standard diet, or a differential effect of PPAR- alpha on its target genes needs to be
postulated under these nonsaturating conditions. In any case, it is clear that in fed mice,
the reduced (compared with starving conditions) expression of most PPAR- alpha target
genes remains independent of L-FABP.
Although our results argue against a substantial transcriptional role of L-FABP
in maintaining hepatic LCFA oxidation in starving mice, elucidation of the precise
mechanism by which LFABP maintains high rates of LCFA oxidation in the liver will
require further work. Our previous results showed that although L-FABP exerts no
effects on cellular LCFA levels, it determines the cytosolic binding capacity for LCFAs
(Martin et al., 2003). The same may turn out true for LCFA-CoA, the proximal enzyme
substrate of LCFA metabolism and itself an L-FABP ligand (Frolov et al., 1997) whose
total levels were not altered in the absence of L-FABP in the present study. Recent
literature indicates that the metabolic availability of LCFA-CoAs is determined by their
binding to specific proteins rather than LCFA-CoA concentration per se (Chao et al.,
2003). Alternatively or in addition, the existence of several long-chain acyl CoA
synthases (Coleman et al., 2002) and subcellular compartmentalization of this metabolite
might lead to local differences in LCFA-CoA concentration.
In conclusion, the results presented here establish for the first time that L-FABP
plays a role in hepatic LCFA oxidation in vivo. Under starving conditions, this role
appears to be mainly direct, rather than through the recently proposed activation of
PPAR- alpha. In contrast, under standard diet, we did see a selective effect of L-FABP
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on hepatic gene expression. It thus appears that the relative importance of L-FABP in
substrate provision and gene expression may vary with physiological condition, a
concept that may be useful for the investigation of various members of the FABP
family.
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CHAPTER IV
     SUMMARY
In the first part of this dissertation, the results provide support for two opposing
effects of intracellular fatty acid flux on skeletal muscle glucose uptake, by decreasing
insulin-dependent glucose uptake and simultaneously increasing basal glucose uptake.
The results show that insulin sensitivity on glucose uptake is improved in H-FABP null
muscle from mice maintained under standard diet. That is, while the maximum effect of
insulin (i.e., insulin responsiveness) seen at supraphysiological insulin levels was
unaltered, low physiological concentrations of insulin caused a significantly larger
increase of deoxyglucose uptake by soleus muscle isolated from H-FABP null as
opposed to wild type mice. This result provides further support for the general notion
that fatty acids or their metabolites metabolism reduce insulin action. But, it is a novel
finding of the present investigation that insulin sensitivity was altered in the absence of
alterations of steady state levels of triglycerides and of both total and individual LCA
CoA. Given that rates of triglyceride synthesis and breakdown are reduced in H-FABP
null soleus muscle (Binas et al., 2003, and present dissertation), these results raise the
question whether lipid turnover as such might be a determinant of insulin sensitivity. 
Circulating insulin levels were dramatically decreased in H-FABP null mice
compared with wild type. This is unlikely due to impaired beta cell function, as a
glucose bolus raised insulin concentrations of H-FABP null and wild type mice to the
same level. More likely and in line with the soleus muscle incubations, increased muscle
insulin sensitivity is the cause of reduced insulin levels, although it may be asked
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whether decreased glucose and/or increased fatty acid levels in H-FABP null mice
exerting an additional influence on the pancreas (Rubi et al., 2002). 
The results also suggest  that in contrast to the absence of an effect of H-FABP
on muscle triglyceride levels under a standard diet, the H-FABP mutation completely
prevented the substantial increase of muscle triglyceride steady state levels normally
caused by a chronic high fat diet. Accumulation of stromal fat (comp. Dobbins et al.,
2001) is an unlikely contributor in this case because the mutation did not raise plasma
fatty acid levels under high fat more than it did under the standard diet. The dramatic
genotypic effect on triglyceride levels under one but not the other diet contrasts with the
rather similar decrements of rates of fatty acid esterification caused by the mutation
under both diets (although the high fat diet was causing an additional decrease).  More
work is needed in order to understand this discrepancy. Total LCA CoA levels were
reduced moderately but not significantly, although some larger (but still non-significant)
individual decreases, in particular linolenoyl CoA and palmitoyl CoA, were seen. These
alterations in lipid levels and turnover induced by the mutation under the high fat diet
were associated with an almost complete prevention of resistance of isolated soleus
muscle glucose transport to supraphysiological insulin concentrations. It should be noted
that the changes of LCA CoA in H-FABP null mice were more moderate than seen in
other rodent models with a comparable degree of insulin resistance (Thompson et al.,
2002; Yu et al., 2002). Although this has been interpreted as supporting a role of LCA
CoA levels in regulating insulin sensitivity, the disparity between the modest changes of
LCA CoA and the dramatic improvement of insulin sensitivity in this and the present
study is striking. These results thus emphasize the need to perform more detailed studies
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to clarify whether acyl CoA levels or some other aspect of LCFA metabolism, such as
lipid turnover, hold the key to regulating insulin-dependent glucose transport. 
The results of ex vivo incubations of isolated soleus muscle from mice kept
under high fat diet are in line with whole body measurements. Although the fat diet led
to impaired glucose clearance in both wild type and H-FABP null mice, the latter
showed a significant improvement compared with wild type. This effect can be
interpreted as a partial prevention of whole body insulin resistance. Incomplete
prevention was expected, as H-FABP is not expressed in white adipose and liver tissue
that also contribute to whole body insulin resistance. Furthermore, insulin levels of H-
FABP null mice maintained under the high fat diet were decreased compared with wild
type, although still increased compared with those on the standard diet. Unlike the
standard diet, however, a bolus of glucose injected into high fat diet-fed H-FABP null
mice did not increase circulating insulin to wild type levels, raising the question of
whether beta cell capacity is reduced.
In summary, the present study of fatty acid metabolism and glucose uptake in H-
FABP deficient skeletal muscles has provided strong evidence of the role of intracellular
fatty acid transport in both insulin-dependent and basal glucose uptake. The mutation
was shown to affect insulin sensitivity under standard diet and high fat diet. Reduced
levels of triglycerides and possibly LCA CoA were associated with an increased
maximum effect of insulin (insulin responsiveness) under the high fat diet, while
unaltered triglyceride and LCFA levels were compatible with improved insulin action at
lower, physiological insulin levels (insulin sensitivity) under the standard diet. These
improvements of insulin action in skeletal muscle occurred despite the increased plasma
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fatty acid levels seen with both diets, supporting the concept that plasma fatty acid levels
are irrelevant in determining muscle insulin sensitivity and responsiveness. Reduced
insulin plasma levels and improved glucose tolerance in H-FABP null mice are also
indicative of improved insulin sensitivity. Our finding of increased insulin sensitivity in
face of normal acyl CoA /triglyceride levels highlights the need for a more detailed
analysis of the role of acyl CoA levels and lipid turnover rates.
The second part of this dissertation revealed a significant role of L-FABP in
hepatic LCFA oxidation, as concluded from the reduced LCFA oxidation and ΒΗΒ
production in isolated L-FABP null hepatocytes. The results are consistent with the
reduced ΒΗΒ levels seen in blood plasma of L-FABP null mice. However, the effect did
not exceed 35% in vitro, whereas at comparable fatty acid concentrations in vivo, it
approached and sometimes exceeded 50%. The reasons for this discrepancy may include
shortcomings of the in vitro model or extrahepatic components of the phenotype, but
they are unlikely to include a reduced provision of substrate (NEFA) to the liver. Indeed,
compared with wild-type mice, plasma NEFA levels were not significantly increased in
female L-FABP null mice during starvation following a standard diet but were
significantly increased under ketogenic diet and starvation after a diabetogenic diet, as
might be expected when fatty acid oxidation is inhibited in a major organ. 
Taken together, the results show that the reduced fatty acid oxidation and
ketogenesis is, at least in part, of intrahepatic origin, demonstrating that L-FABP is a
cell-intrinsic stimulator of LCFA oxidation. The increase in plasma fatty acid levels
under some ketogenic conditions also implies that LFABP impacts whole body lipid
metabolism, a conclusion that can be extended to non-ketogenic conditions. Both plasma
71
NEFA and triacylglycerols were increased in (at least in female) L-FABP null mice after
a chronic diabetogenic diet (without starvation), conceivably due to reduced hepatic
clearance. The mechanisms underlying the altered plasma levels in non-ketogenic
conditions clearly deserve further investigation.
The second question addressed in this part of the dissertation concerned the
mechanism by which L-FABP stimulates LCFA oxidation. Although the high
cytoplasmic concentration of L-FABP in fully differentiated hepatocytes is suggestive of
a substrate-level function, L-FABP concentrations were recently shown to limit the
activity of the lipid-dependent transcription factor PPAR-alpha in PPAR-alpha -
transfected cells (Wolfrum et al., 2001; Kersten et al., 1999; and present dissertation).
This suggested that the transcription of PPAR- alpha target genes, and consequently the
capacity for fatty acid oxidation, might be compromised in the absence of LFABP.
Ketogenesis from endogenous substrates is severely impaired in both PPAR- alpha null
mice (Wolfrum et al., 2001; Kersten et al., 1999; and present dissertation) and L-FABP
null mice (present study). However, we found that ketogenesis from medium-chain fatty
acid (octanoate) is reduced only in PPAR- alpha null mice, whereas octanoate boosted
ketogenesis in L-FABP null mice to levels higher than achievable in wild-type mice by
the fat diet or starvation, showing that the capacity for ketogenesis was fully maintained.
This difference in ketogenic capacity can be explained by differences in gene
expression.
 In addition, following starvation, levels of the mRNAs encoding MCAD and
mitochondrial HMG CoA synthase were reduced in the PPAR-alpha null vs. wild-type
mice. In contrast, they were normal in the L-FABP null mice. Thus, at least some
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PPAR-alpha target genes and the associated biochemical process were not affected in
starving LFABP null mice. Two other PPAR- alpha target genes, ACO and CYP4A3,
representing peroxisomal and microsomal lipid oxidation, respectively, were also
expressed normally, suggesting that PPAR- -dependent gene transcription was generally
unaffected in the starving L-FABP null mice investigated. In line with this, PPAR- alpha
mRNA levels were also normal. Finally, the normal levels of the mRNAs encoding
LCAD and L-CPT1 suggest that reduced hepatic LCFA oxidation in the starving L-
FABP null mice was not caused by altered gene expression through PPAR- alpha -
independent gene transcription either. In agreement with this conclusion, we did not find
a reduced rate of palmitic acid oxidation in liver homogenates of L-FABP null mice,
arguing that the levels of all enzymes involved in LCFA oxidation and ketogenesis are
maintained. In fact, because the principal difference between intact isolated hepatocytes
and liver homogenates is that in the latter, plasma membranes are disrupted and the
oxidative substrate is bound by another carrier (albumin), the oxidation defect is most
likely at the level of intracellular substrate provision.
Taken together, the results of this research do not support a role for L-FABP in
PPAR- alpha function or indeed gene expression in general under starvation conditions
in vivo. In this respect, I note that similar to L-FABP null hepatocytes, H-FABP null
cardiomyocytes lack compensatory FABP expression, show substantially reduced LCFA
oxidation (while maintaining normal oxidative capacity), and oxidize octanoic acid
normally . In contrast, octanoic acid oxidation is significantly impaired in PPAR- alpha
null hearts.
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